Next Article in Journal
Transcranial Laser Stimulation Research—A New Helmet and First Data from Near Infrared Spectroscopy
Next Article in Special Issue
Scabiosa Genus: A Rich Source of Bioactive Metabolites
Previous Article in Journal
Acupuncture and Lifestyle Myopia in Primary School Children—Results from a Transcontinental Pilot Study Performed in Comparison to Moxibustion
Previous Article in Special Issue
The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicines
Volume 5
Issue 3
10.3390/medicines5030096
medicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Protein Targets of Frankincense: A Reverse Docking Analysis of Terpenoids from Boswellia Oleo-Gum Resins

by
Kendall G. Byler
1 and
William N. Setzer
1,2,*
1
Department of Chemistry, University of Alabama in Huntsville, Huntsville, AL 35899, USA
2
Aromatic Plant Research Center, 230 N 1200 E, Suite 102, Lehi, UT 84043, USA
*
Author to whom correspondence should be addressed.
Medicines 2018, 5(3), 96; https://doi.org/10.3390/medicines5030096
Submission received: 19 July 2018 / Revised: 24 August 2018 / Accepted: 28 August 2018 / Published: 31 August 2018
(This article belongs to the Special Issue Biological Potential and Medical Use of Secondary Metabolites)
Browse Figures
Versions Notes

Abstract

:
Background: Frankincense, the oleo-gum resin of Boswellia trees, has been used in traditional medicine since ancient times. Frankincense has been used to treat wounds and skin infections, inflammatory diseases, dementia, and various other conditions. However, in many cases, the biomolecular targets for frankincense components are not well established. Methods: In this work, we have carried out a reverse docking study of Boswellia diterpenoids and triterpenoids with a library of 16034 potential druggable target proteins. Results: Boswellia diterpenoids showed selective docking to acetylcholinesterase, several bacterial target proteins, and HIV-1 reverse transcriptase. Boswellia triterpenoids targeted the cancer-relevant proteins (poly(ADP-ribose) polymerase-1, tankyrase, and folate receptor β), inflammation-relevant proteins (phospholipase A2, epoxide hydrolase, and fibroblast collagenase), and the diabetes target 11β-hydroxysteroid dehydrogenase. Conclusions: The preferential docking of Boswellia terpenoids is consistent with the traditional uses and the established biological activities of frankincense.

Graphical Abstract

1. Introduction

The genus Boswellia (Burseraceae) is made up of resiniferous trees and shrubs that are distributed across India, the Arabian peninsula, and Africa [1,2]. The genus is known for its aromatic terpenoid oleo-gum resin, frankincense. Frankincense has been a part of human religious ceremonies and ethnobotany for thousands of years [3]. Important frankincense-producing species include B. carteri, which grows in Somaliland and Puntland [1], B. sacra, found in Yemen, southern Oman, Somalia, and Somaliland [2], B. frereana, which is endemic to Somalia [2], B. papyrifera, primarily found in Sudan, Eritrea, and Ethiopia [4], and B. serrata, which grows primarily in India [5].
Frankincense oleo-gum resin has been used traditionally to treat wounds [6], to treat inflammatory diseases [7], for oral hygiene [8], as well as for its psychoactive effects [9,10]. The biological activities of frankincense have been attributed to its essential oils [11] and its non-volatile diterpenoids and triterpenoids [6]. Although frankincense has been used for various maladies and conditions, and numerous biological activities have been attributed to frankincense, the particular biological targets are not well established. In this work, we have carried out a reverse molecular docking study of Boswellia cembranoid diterpenoids (Figure 1), cneorubenoid diterpenoids (Figure 2), and triterpenoids (Figure 3) against a library of 16,034 potential druggable target proteins.
The cembranoids incensole and incensole acetate were detected in the oleo-gum resin of B. papyrifera, while serratol was found in B. carteri, B. sacra, and B. serrata [12]. The boscartins have been isolated from the oleo-gum resin of B. carteri [13]. Incensole oxide has been isolated from B. carteri and the X-ray crystal structure determined [13,14]; both incensole oxide and incensole oxide acetate have been detected in small concentrations in the essential oil from the resin of B. papyrifera [15]. Isoincensole oxide [16,17] and isoincensolol [17] were isolated from B. carteri resin. Verticilla-4(20),7,11-triene and serratol and were isolated from B. carteri [18] and B. serrata [19], respectively.
Boswellia carteri oleo-gum resin is the source of several prenylated aromadendrane (cneorubenoid) diterpenoids (Figure 2) [20,21].
Numerous ursane, oleanane, lupane, dammarane, and tirucallane triterpenoids have been isolated and characterized from Boswellia species (Figure 3) [22]. Boswellia serrata has yielded α-boswellic acid, β-boswellic acid, 3-acetyl-α-boswellic acid, 3-acetyl-β-boswellic acid, 11-keto-β-boswellic acid, and 3-acetyl-11-keto-β-boswellic acid [23]. Boswellia carteri has yielded the oleanane triterpenoids α-boswellic acid, and 3-acetyl-α-boswellic acid; the ursane triterpenoids β-boswellic acid, 3-acetyl-β-boswellic acid, 11-keto-β-boswellic acid, 3-acetyl-11-keto-β-boswellic acid, 3-acetyl-11α-methoxy-β-boswellic acid, 9,11-dehydro-β-boswellic acid, and 3-acetyl-9,11-dehydro-β-boswellic acid; the lupane triterpenoids lupeolic acid and 3-acetyl lupeolic acid; and the tirucallane triterpenoids α-elemolic acid, β-elemonic acid, 3α-hydroxytirucalla-7,24-dien-21-oic acid, 3α-acetoxytirucalla-7,24-dien-21-oic acid, and 3β-hydroxytirucalla-7,24-dien-21-oic acid [24]. Olibanumols A, B, C, H, I, J’ [25], E, F, G [20], K, L’, M, and N [26] have been isolated from the oleo-gum resin of B. carteri. B. carteri resin has also yielded boscartenes L, M, and N, as well as trametenolic acid B, 3-oxotirucalla-7,9(11),24-trien-21-oic acid, and (20S)-3,7-dioxo-tirucalla-8,24,-dien-21-oic acid [27].

2. Materials and Methods

2.1. Ligand Preparation

Each ligand structure was prepared using Spartan’16 v. 2.0.7 (Wavefunction, Inc., Irvine, CA, USA). The lowest-energy conformations of the ligands were determined using the Merck Molecular Force Field (MMFF) [28]. In the case of the cembranoid macrocyclic ligands, further conformational analysis was carried out using density functional theory at the M06-2X/6-31G* level [29] with SM8 [30] aqueous solvent model [31].

2.2. Reverse Molelcular Docking

A reverse molecular docking study was carried out on each of the Bosellia terpenoids with the sc-PDB database of druggable binding sites [32]. Each compound was examined against the 16034 protein targets contained in the sc-PDB database. Prior to docking, all solvent molecules were removed from the protein structures. Co-crystallized enzyme cofactors were retained as cofactors and co-crystallized substrates or inhibitors were retained as ligands. Molecular docking was carried out using Molegro Virtual Docker v. 6.0.1 (Molegro ApS, Aarhus, Denmark) [33] as previously reported [34]. A python script was written to generate the Molegro input files; the jobs were run as a batch from the mvd.exe command line executable. The script took the co-crystallized ligands in each protein and wrote an input file that defined the search space for that docking as a sphere centered on the ligand’s center of mass. A 15-Å radius sphere was centered on the binding sites of each protein structure in order to permit each ligand to search. Standard protonation states of each protein, based on neutral pH, were used and charges were assigned based on standard templates as part of the Molegro Virtual Docker program. Each protein was used as a rigid model without protein relaxation. Flexible-ligand models were used in the docking optimizations. Different orientations of the ligands were search and ranked based on their “rerank” energy scores. A total of 100 runs for each ligand were carried out.

2.3. Conformational Analysis of Boscartol D

All calculations were carried out using Spartan’16 for Windows (Wavefunction, Inc., Irvine, CA, USA). Conformational profiles were carried out using molecular mechanics with the MMFF force field. Conformations with relative energies <20 kJ/mol were re-evaluated, with geometry optimization, using density functional theory (DFT, M06-2X/6-31G*) with a nonpolar solvent (CHCl3) model.

3. Results and Discussion

3.1. Cembranoid Diterpenoids

The macrocyclic cembranoid diterpenoids examined in this study are shown in Figure 1. The top-binding protein targets for each of the Boswellia cembranoids are summarized in Table 1. Included in Table 1 are the median docking energies for comparison. The top binding proteins for boscartin A were acetylcholinesterase (AChE) enzymes, Torpedo californica (TcAChE) and human (HsAChE). Boscartin B docked preferentially with human N-acetylgalactosaminyltransferase (HsGTA) as well as with the bacterial targets Serratia marcescens chitinase B (SmChiB), Helicobacter pylori peptide deformylase (HpPDF), and Mycobacterium tuberculosis 7,8-diaminopelargonic acid synthase (MtBioA). The proteins with the most exothermic docking for boscartin C were Escherichia coli aspartate transaminase (EcAspTA), murine acetylcholinesterase (MmAChE), and Daboia russelii (Russell’s viper) phospholipase A2 (DrPLA2). Boscartin D showed excellent docking with TcAChE (PDB 2cek, Edock = −115.3 kJ/mol) and EcAspTA. The best protein targets for boscartin E were TcAChE, HpPDF, and MtBioA. Boscartin F showed preferential docking energies with human pyruvate kinase M2 (HsPKM2), TcAChE, and HpPDF. Boscartin G showed excellent docking properties with acetylcholinesterases TcAChE and HsAChE. The proteins with the most exothermic docking energies with boscartin H were human N-acetylgalactosaminyltransferase (HsGTA), DrPLA2, SmChiB, and MmAChE.
Incensole docked well with TcAChE, human aldo-keto reductase 1C3 (HsAKR1C3), and SmChiB. Incensole acetate preferentially targeted bacterial proteins EcAspTA, HpPDF, and Burkholderia cepacia phenazine biosynthesis protein A/B (BcPhzA/B). The preferred protein targets for incensole oxide were EcAspTA, human immunodeficiency virus type 1 reverse transcriptase (HIV-1-RT), TcAChE, BcPhzA/B, and MtBioA. Incensole oxide acetate gave excellent docking energies to EcAspTA, TcAChE, MmAChE, and HIV-1-RT. Isoincensole oxide docked well to BcPzhA/B and TcAChE. The protein targets that showed the best docking energies with isoincensolol were DrPLA2, Staphylococcus aureus multidrug binding protein QacR (SaQacR), and human dehydroepiandrosterone sulfotransferase (HsSULT2A1).
Every cembranoid ligand showed excellent docking properties to acetylcholinesterases (Table 2). Acetylcholinesterase has been identified as a target for treatment of Alzheimer’s disease [35]. This is notable because frankincense (Boswellia spp.) resins have been used in Persian traditional medicine as an anti-Alzheimer’s agent [36,37]. Animal models (rat) of Alzheimer’s disease [38,39,40] and human clinical trials [41,42] showed beneficial effects on memory with frankincense.
The lowest-energy docked pose of boscartin G with TcAChE (PDB 1e66, Figure 4A) shows the ligand to adopt the lowest-energy conformation as calculated by density functional theory at the M06-2X/6-31G*/SM8 level [31]. Key interactions between boscartin G and TcAChE are hydrophobic interactions between the ligand and aromatic amino acid side chains of Trp84, Phe330, and His440 (Figure 4B). In addition, there are hydrogen-bonding interactions between the oxirane ring of the ligand and the phenolic -OH of Tyr121 and the C(11)-OH of the ligand and the peptide C=O of His440 (Figure 4B).
Boscartin A occupies the active site of TcAChE (Figure 5A, PDB 2cek). As observed for boscartin G with TcAChE, key interactions between the docked ligand and the protein are hydrophobic interactions with Trp84, Phe330, and His440, and a hydrogen-bond between the C(11)-OH of the ligand and the His440 peptide C=O. The conformation of the lowest energy docked pose of boscartin A (Figure 5A) is the same as the lowest-energy calculated (M06-2X/6-31G*/SM8, Figure 5B) [31] and not that found in the X-ray crystal structure [13].
A number of bacterial proteins were targeted by Boswellia cembranoids (Table 3). Helicobacter pylori peptide deformylase (HpPDF) and Escherichia coli aspartate transaminase (EcAspTA) were particularly well targeted, while boscartin C and E and incensole oxide acetate showed remarkably exothermic docking energies. Boswellia resin extracts have shown in-vitro antibacterial activity [43,44,45], and frankincense resins have been used traditionally to treat wounds [6,46] and for oral hygiene [8]. Furthermore, B. papyrifera resin has shown activity against methicillin-resistant Staphylococcus aureus (MRSA) [47] and B. serrata resin showed activity in a clinical trial against plaque-induced gingivitis [48]. The selective targeting of bacterial proteins by Boswellia cembranoids corroborates the traditional medicinal uses and the demonstrated antibacterial activities of frankincense.
The potent docking properties of Boswellia cembranoids with HpPDF are particularly noteworthy. There is a strong association between colonization of the human stomach by Helicobacter pylori and gastrointestinal illnesses such as chronic gastritis and peptic ulcers [49]. Frankincense has been used traditionally to treat stomach disturbances [4] and ulcers [46]. In addition, Boswellia extracts have been shown in clinical studies to be helpful in treating ulcerative colitis [50].
Boscartin G is the strongest binding Boswellia cembranoid ligand with HpPDF (PDB 2ew5). The lowest-energy docked pose is shown in Figure 6. Boscartin G occupies the active site of HpPDF at the same location as the co-crystallized ligand, 4-{(1E)-3-oxo-3-[(2-phenylethyl)amino]- prop-1-en-1-yl}-1,2-phenylene diacetate, a cavity surrounded by Ile45, Gly95, Glu94, His138, Cys96, and Gly46 (Figure 6B). The ligand forms two hydrogen-bonds with the peptide N-H groups of Ile45 and Gly46. The docked structure of boscartin G with HpPDF shows the same conformation (Figure 6C) as that predicted from DFT calculations (Figure 6D) [31].
Several Boswellia cembranoids showed selective docking to HIV-1 reverse transcriptase (HIV1-RT) (Table 4). In particular, incensole oxide acetate showed excellent docking (Edock < −100 kJ/mol) to four of the seven HIV1-RT protein crystal structures. The lowest-energy docked pose of incensole oxide acetate with HIV-1 reverse transcriptase (PDB 3mee) is shown in Figure 7. Key interactions between the ligand and the protein are Tyr181, Tyr188, Leu100, Trp229, and Lys103 (Figure 7B). Interestingly, the docking energies for the cembranoids to PDB 3lal and 3t19 are, on average, lower than for the other protein structures. The differences in docking energies can be attributed to the arrangements of the amino acid residues at the binding sites, resulting in different orientations of the docked ligands. Thus, for example, the key amino acids interacting with incensole oxide acetate in PDB 3lal are Tyr188, Leu100, Tyr181, Phe227, and Tyr318 (Figure 7C), while PDB 3t19 had Leu100, Tyr188, Val106, Tyr318, and Tyr181 (Figure 7D). That is, binding sites of the protein crystal structures are heavily influenced by the co-crystallized ligands. Both methanol and aqueous extracts of Boswellia carteri have demonstrated HIV-1 reverse transcriptase activity [51].

3.2. Cneorubenoid Diterpenoids

The cneorubenoid diterpenoids, boscartols A–I and olibanumol D, can be considered to be prenylated aromadendranes (Figure 2), and have been isolated from the oleo-gum resin of Boswellia carteri [21]. The absolute configuration of the C(15) of boscartol D was not experimentally determined [21]. Nevertheless, both diastereomers, (15R)-boscartol D and (15S)-boscartol D were used in the reverse docking. In addition, the stereochemistry of C(15) was determined theoretically using density functional theory (DFT) conformational analysis carried out at the M06-2X/6-31G* level of theory, including a non-polar (CHCl3) solvent model. A complete conformational analysis of (15R)-boscartol D was carried out giving 20 low-energy conformations (Erel < 14.0 kJ/mol, accounting for 100% of the Boltzmann distribution of conformers). Similarly, conformational analysis of (15S)-boscartol D returned 13 low-energy (Erel < 13.0 kJ/mol). For each of the conformations, the H-C(15)-C(16)-H dihedral angle was determined and the corresponding vicinal coupling constants (3JHH) calculated using both the original Karplus equation [52] and the Haasnoot/Altona generalized Karplus equation that includes correction terms for the electronegativity of substituents [53]. Accounting for the Boltzmann distribution, (15R)-boscartin D is predicted to have 3JHH of 4.3 and 5.1 Hz, respectively. The (15S)-diastereomer, on the other hand, is calculated to have 3JHH of 6.3 and 6.5 Hz, respectively. The reported 3JHH coupling constant was 7.6 Hz [21]. Based on the calculated 3JHH coupling constants, the stereochemistry of boscartol D is predicted to be (15S).
The protein targets that showed the best docking properties with Boswellia cneorubenoids are listed in Table 5, along with median docking energies. The protein that was best targeted by Boswellia cneorubenoids was Bacillus anthracis nucleotide adenylyltransferase (BaNadD, PDB 3hfj) with seven of the 11 ligands showing docking energies <−120 kJ/mol. Human folate receptor β (HsFRβ, PDB 4kn0 and 4kn1) was also well targeted with 7/11 cneorubenoids with Edock < −120 kJ/mol. The strongest docking ligands were boscartol E and boscartol I, and both of these ligands targeted BaNadD (PDB 3 hfj) and HsFRβ (PDB 4kn0) very well.
Nicotinate mononucleotide adenylyltransferase (NadD) has been identified as a target for development of antibacterial agents. The excellent docking of cneorubenoids with BaNadD, along with the known antibacterial activity of frankincense [43,44,45], corroborates the traditional uses of frankincense to treat wounds [6,46].
Bacillus anthracis NadD (PDB 3hfj) is a dimeric structure with the active site at the interface of the two protein monomers (Figure 8). The active site is a hydrophobic pocket formed by Trp116A, Trp116B, Tyr112A, Tyr112B, Lys115A, and Lys115B (Figure 8B).
Human folate receptor β (HsFRβ) is overexpressed in activated macrophages associated with pathogenesis of inflammatory and autoimmune diseases [54] as well as neoplastic tissues [55]. Thus, antifolates that target folate receptors could be useful for the treatment of cancer and inflammatory diseases [56]. Clinical trials have demonstrated the encouraging results of frankincense treatment for inflammatory and autoimmune diseases such as rheumatoid arthritis, osteoarthritis, Crohn’s disease, and collagenous colitis [57]. Boswellia cneorubenoids may be playing a role in the anti-inflammatory activity of frankincense.
The boscartols docked with HsFRβ in the folate binding site (Figure 9). The cyclopropazulane ring is surrounded by aromatic amino acids Trp187, Tyr101, Tyr76, and Phe78 (Figure 9B). In the case of boscartol A and boscartol B, the terminal –OH group is held in place by hydrogen bonds to Ser73 and Phe78 (Figure 9B).

3.3. Boswellia Triterpenoids

The Boswellia triterpenoids examined in this reverse docking study are shown in Figure 3 and the target proteins with the best docking energies for each triterpenoid ligand are summarized in Table 6. The most receptive protein targets for Boswellia triterpenoids were Staphylococcus aureus multidrug binding protein (SaQacR, PDB 3bt9) with an average docking energy (Edock) of −111.9 kJ/mol and human fibroblast collagenase (PDB 1cgl) with an average docking energy (Edock) of −110.5 kJ/mol.
The best overall triterpenoid ligand-protein target pairs were boscartene N with human tankyrase 2 (HsTANK2, PDB 3ua9), Edock = −157.2 kJ/mol; 3α-hydroxytirucalla-7,24-dien-21-oic acid with HsTANK2, Edock = −154.3 kJ/mol; α-elemolic acid with HsTANK2, Edock = −152.7 kJ/mol; 3-oxotirucalla-7,9(11),24-trien-21-oic acid with HsTANK2, Edock = −151.0 kJ/mol; 3α-acetoxytirucalla-7,24-dien-21-oic acid with human glucokinase (PDB 4ixc), Edock = −150.4 kJ/mol; isofouquieryl acetate with Guinea pig (Cavia porcellus) 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1, PDB 3lz6), Edock = −150.1 kJ/mol; 3β-acetoxy-20S,24S-dihydroxydammar-25-ene with Enterobacter cloacae pentaerythritol tetranitrate reductase (EcPETNR, PDB 2aba), Edock = −149.9 kJ/mol; and 3β-acetoxydammar-24-ene-16β,20R-diol with Guinea pig 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1, PDB 3lz6), Edock = −149.6 kJ/mol.
Frankincense oleo-gum resins have been used in traditional medicine to treat a variety of inflammatory conditions, including arthritis, colitis, and asthma [58,59]. Boswellic acids, including β-boswellic acid, 11-keto-β-boswellic acid, and acetyl-11-keto-β-boswellic acid, have been implicated in the anti-inflammatory properties of Boswellia resins; these triterpenoid components are involved in inhibition of 5-lipoxygenase (5-LOX), inducible nitric oxide synthase (iNOS), cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) [60].
In-silico screening of the Boswellia triterpenoids was carried out against molecular targets of inflammation, including human pancreatic secretory phospholipase A2 (HsPLA2), porcine pancreatic phospholipase A2 (SsPLA2), human phosphoinositide 3-kinase (HsPI3K), human interkeukin-1 receptor associated kinase 4 (HsIRAK4), human glutathione transferase omega 1 (HsGSTO1), human 5-lipoxygenase (Hs5-LOX), mouse inducible nitric oxide synthase (MmiNOS), ovine COX-1 (OaCOX-1), murine COX-2 (MmCOX-2), human fibroblast collagenase (matrix metalloproteinase-1, HsMMP-1), murine soluble epoxide hydrolase 2 (MmEPHX2), human endoplasmic reticulum aminopeptidase 2 (HsERAP2), human soluble epoxide hydrolase 2 (HsEPHX2), and human phosphodiesterase 4B (HsPDE4B). The docking energies of the triterpenoid ligands with inflammatory target proteins are shown in Table 7.
The Boswellia triterpenoids showed relatively weak docking to 5-LOX, iNOS, PI3K, IRAK4, or GSTO1, and no docking at all to either COX-1 or COX-2 (positive docking energies). However, several Boswellia triterpenoids showed relatively strong docking (Edock < −120 kJ/mol) to human endoplasmic reticulum aminopeptidase 2 (HsERAP2), including 3β-acetoxy-20S,24S- dihydroxydammar-25-ene, 3β-acetoxydammar-24-ene-16β,20R-diol, isofouquieryl acetate, ocotillyl acetate, olibanumol J, and olibanumol J’. There is a significant association of ERAP2 with psoriatic arthritis [61], and notably, Boswellia triterpenoids have shown promise for the treatment of psoriasis [62]. Similarly, inhibitors of phosphodiesterase 4B have shown promise in the treatment of psoriasis and atopic dermatitis [63], and isofouquierol and olibanumol J’ showed good docking properties with HsPDE4B with docking energies of −128.3 and −128.8 kJ/mol, respectively. The only other strong docking observed was olibanumol J with murine soluble epoxide hydrolase 2 (MmEPHX2), 3α-acetoxytirucalla-7,24-dien-21-oic acid with human matrix metalloproteinase-1 (HsMMP-1), (20S)-3,7-dioxotirucalla-8,24-dien-21-oic acid with porcine pancreatic phospholipase A2 (SsPLA2), and 3β-acetoxy-20S,24-dihydroxydammar-25-ene with human pancreatic secretory phospholipase A2 (HsPLA2). The targeting of matrix metalloproteinase-1 (fibroblast collagenase) is noteworthy; B. serrata extract has shown clinical efficacy as a treatment for osteoarthritis of the knee [64].
Note that β-boswellic acid, 11-keto-β-boswellic acid, and 3-acetyl-11-keto-β-boswellic acid had relatively weak docking with inflammation-relevant protein targets. It may be that these Boswellia triterpenoids, rather than inhibiting particular enzyme targets, are inhibiting the secretion of pro-inflammatory cytokines such as tumor necrosis factor α (TNFα), interleukin 1 (IL-1), IL-6, IL-12, IL-18, or interferon γ (IFN-γ) [65].
Olibanumols G, H, I, and J all showed selective docking to S. aureus multidrug binding protein (SaQacR). The olibanumols occupy the binding site of SaQacR, same site as the co-crystallized ligand in PDB 3bti (Figure 10). The site is made up of aromatic amino acids Trp61, Tyr93, and Tyr123, forming a hydrophobic pocket. The triterpenoid ligand olibanumol J also has a hydrogen-bonding interaction between C(3)-OH of the ligand and the amide C=O of Ala153. Other key interacting amino acids in the binding site are Ser86, Glu90, and Asn157. In addition to the olibanumols, six additional triterpenoids also showed selective docking to SaQacR, 3-acetoxy-12,20(29)-lupadien-24-oic acid, lupeolic acid, 3-oxotirucalla-7,9(11),24-trien-21-oic acid, 4,23-dihydroburic acid, 9,11-dehydro-β-boswellic acid, and boscartene N.
Another antibacterial target protein that showed good docking properties was Enterobacter cloacae pentaerythritol tetranitrate reductase (EcPETNR) with seven Boswellia dammarane triterpenoids showing selective docking to this target, 3β-acetoxy-20S,24-dihydroxydammar-25-ene (both diastereomers), 3β-acetoxydammar-24-ene-16β,20R-diol, dammarenediol II acetate, isofouquierol, isofouquieryl acetate, and ocotillyl acetate. These dammarane triterpenoids occupy the active site of EcPETNR, near to the riboflavin monophosphate redox cofactor, with very similar docked poses (Figure 11). Key intermolecular contacts are hydrogen bonding of the C(3) acetoxygroup with Arg142, hydrogen-bonding of C(20)-OH with the riboflavin monophosphate cofactor and His184 (Figure 11B). In the case of 3β-acetoxy-20S,24S-dihydroxydammar-25-ene, there is also a hydrogen-bond between the C(24)-OH group and Asp274.
Drugs that reversibly inhibit acetylcholinesterase are currently being explored to treat Alzheimer’s disease [66], and Torpedo californica and murine acetylcholinesterases have been used as model enzyme targets for anticholinesterase inhibition [67]. β-Boswellic acid and its derivatives (11-keto-β-boswellic acid, 11-ethoxy-β-boswellic acid, 3-acetyl-β-boswellic acid, and 3-acetyl-11-keto-β-boswellic acid) showed selective docking to Torpedo californica acetylcholinesterase (TcAChE, PDB 3i6m). Interestingly, increasing oxygenation resulted in more exothermic docking energies (−118.1, −120.8, −124.6, −128.3, and −129.7 kJ/mol, respectively). These β-boswellic acid derivatives all adopt the same lowest-energy poses in the active site of the enzyme (Figure 12). It is tempting to suggest that the ordering of docking energies is due to increasing hydrogen-bonding of the more oxygenated ligands. However, the only hydrogen bonding seen is with the C(3)-substituent of the ligand (either –OH or –OAc) with Tyr121 (see Figure 10B. Note that the active site of the acetylcholinesterase is surrounded by aromatic amino acids (Trp84, Tyr334, Tyr121, Phe330, Phe331, and Trp279). The more important interactions, therefore, are van der Waals hydrophobic interactions between the ligand and the aromatic amino acids. The trend in docking energies for these β-boswellic acid derivatives is likely due to the increased number of heavy atoms and increasing molecular weight. Olibanumols K, L’, M, and N also showed selective docking to acetylcholinesterase proteins. The strongest-docking triterpenoid ligands to TcAChE were 4,23-dihydroburic acid (Edock = −135.8 kJ/mol) and 3-acetoxy-5,12-ursadien-24-oic acid (Edock = −131.7 kJ/mol); olibanumol N docked strongly with MmAChE (Edock = −133.0 kJ/mol). The excellent docking properties of Boswellia triterpenoid ligands to acetylcholinesterase supports the clinical use of frankincense to treat Alzeimer’s disease [41].
Several protein targets related to cancer were targeted by Boswellia triterpenoids, including poly(ADP-ribose) polymerase-1 (PARP-1), tankyrase-1 (TANK1), tankyrase-2 (TANK2), folate receptor β (FRβ), and histone deacetylase (HDAC). Poly(ADP-ribose) polymerase-1 (PARP-1) is an important enzyme for the repair of single-strand DNA breaks, and inhibition of PARP-1 can cause multiple double strands DNA breaks to occur, leading to cell death [68]. Several types of cancers are more dependent on PARP-1 than normal cells, so PARP-1 has become an attractive target for cancer chemotherapy [69,70]. At least 15 Boswellia triterpenoids showed selective docking to PARP-1 (see Table 6). The strongest-docking ligands for human PARP-1 were (20S)-3,7-dioxotirucalla-8,24-dien-21-oic acid (Edock = −141.8 kJ/mol) and eupha-2,8,22-triene-20,24R-diol (Edock = −139.8 kJ/mol).
Folate receptors are overexpressed in cancer cells, presumably due to the increased requirement of cancer cells for folic acid needed in cell proliferation [71] and folate receptor-β is overexpressed in lung, liver, skin, and soft tissue tumors, as well as associated stromal cells. Folate receptors, therefore, show promise as chemotherapeutic targets for cancer and other human pathologies [72]. Three of the Boswellia triterpenoids in this study showed excellent docking properties to human folate receptor β (HsFRβ), namely dammarenediol II acetate, isofouquierol, and isofouquieryl acetate, with docking energies of −132.3, −130.4, and −137.0 kJ/mol, respectively.
Histone deacetylases (HDAC) are enzymes that remove acetyl groups from lysine residues of histones, which allow the histones to envelope DNA more tightly. Thus, HDACs can affect cell growth and differentiation and cell death [73,74]. Histone deacetylase has been recognized as a promising target for cancer chemotherapy [75,76]. Reverse docking of Boswellia triterpenoids has revealed α-elemolic acid to preferentially dock to Aquifex aeolicus histone deacetylase (AaHDAC).
Frankincense-containing formulations had been used in ancient Greece for treating various malignant tumors [77]. Frankincense has been used in the Indian traditional medicine (Ayurveda) and in Traditional Chinese Medicine (TCM) as a treatment for proliferative diseases [78]. In addition, extracts of frankincense oleo-gum resins have shown in-vitro cytotoxic activity on several human tumor-derived cell lines [58,79,80,81], and these activities have been attributed to boswellic acids [82]. Interestingly, although β-boswellic acid [83] and 3-acetyl-11-keto-β-boswellic acid [84] have shown antineoplastic activities, this reverse-docking study did not reveal particularly notable docking properties to cancer-relevant protein targets. It may be that the boswellic acids and derivatives are targeting inflammatory pathways [85,86] or multiple targets as their mechanisms of antineoplastic activities [82,84].
Several Boswellia triterpenoids showed good docking properties to 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1). For example, the dammarane triterpenoids 3β-acetoxy- 20S,24-dihydroxydammar-25-ene, 3β-acetoxydammar-24-ene-16β,20R-diol, dammarenediol II, dammarenediol II acetate, isofouquierol, and isofouquieryl acetate showed excellent docking energies with Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1, PDB 3lz6). These dammarane triterpenoids all occupy the same position in the active site of the enzyme, blocking access to the NADPH cofactor (Figure 13). The docked dammaranes are sandwiched between the NADPH cofactor and hydrophobic amino acids Tyr152, Tyr98, Tyr158, Leu192, and Tyr206 (Figure 13B). There are also close contacts, but no apparent hydrogen-bonds, with Thr197 and Asn99. 11β-Hydroxysteroid dehydrogenase type 1 mediates the interconversion of cortisone and cortisol and overexpression of 11βHSD1 can lead to metabolic disease, characterized by visceral obesity, hyperlipidemia, hypertension, glucose intolerance, insulin resistance, and type II diabetes [87,88]. Thus, inhibition of 11βHSD1 may serve as a treatment option for metabolic syndrome and type II diabetes [89,90].
Boswellia serrata is used traditionally by diabetic patients in Iran, and B. serrata supplementation has shown clinical benefit in blood lipid and glucose levels in type II diabetic patients [91,92]. Furthermore, B. serrata resin extract has been shown to prevent increase in blood glucose levels in streptozotocin-induced diabetic mice [93]. Similarly, B. glabra extracts have shown hypoglycemic effects in alloxan-induced diabetic rats [94]. The selective targeting of Guinea pig 11βHSD1 and human 11βHSD1 by Boswellia triterpenoids is consistent with the traditional use and anti-diabetic activities of Boswellia oleo-gum resin.
Oxidosqualene cyclases (OSCs) are enzymes that catalyze the cyclization of 2,3-epoxysqualene to form triterpenoids or steroids [95]. In mammals, cyclization of 2,3-epoxyaqualene leads to lanosterol, which can then be converted to cholesterol [96]. Inhibition of oxidosqualene cyclase, therefore, has emerged as a viable therapeutic option to treat hypercholesterolemia and atherosclerosis [97,98]. The oxidosqualene-hopene cyclase from the thermophilic bacterium Alicyclobacillus acidocaldarius is homologous to the human enzyme and has been crystallized with OSC inhibitors [99]. Several triterpenoid ligands, most notably ocotillyl acetate, 3β-acetoxydammar-24-ene-16β,20R-diol, and dammarenediol II acetate, docked well to AaOSC with docking energies of −144.6, −139.2, and −138.9 kJ/mol, respectively. These dammarane triterpenoids adopt the same positions in the active site of the enzyme (Figure 14). The active site of AaOSC is a hydrophobic pocket composed of Trp489, Trp169, Phe365, Ile261, Trp312, Phe601, and Tyr420. In addition, there is a hydrogen bond formed between the C(24)-OH of the ligand and the phenolic -OH of Tyr609. The structural similarities between triterpenoids and steroids are likely responsible for the docking properties of Boswellia triterpenoids to OSCs.

4. Conclusions

Numerous Boswellia terpenoid components have shown selective docking to bacterial protein targets, antineoplastic molecular targets, diabetes-relevant targets, protein targets involved in inflammatory disease conditions, and the Alzheimer’s disease target acetylcholinesterase. The molecular docking properties of Boswellia terpenoid components corroborate the traditional uses of frankincense, the clinical efficacy of frankincense, and the biological activities of Boswellia oleo-gum resins and components. Furthermore, the biomolecular targets identified in this work should lead to further exploration of development and improvement of inhibitors to treat these various disease states.

Author Contributions

K.G.B. and W.N.S. contributed equally to the computational work and manuscript preparation.

Funding

This research was partially funded by dōTERRA International (Pleasant Grove, UT, USA).

Acknowledgments

This work was carried out as part of the activities of the Aromatic Plant Research Center (APRC, https://aromaticplant.org/). The authors are grateful to dōTERRA International (https://www.doterra.com/US/en) for financial support of the APRC.

Conflicts of Interest

The authors declare no conflicts of interest. The funding sponsor, dōTERRA International, played no role in the design of the study; in the collection, analysis, or interpretation of the data; conclusions of the study; or in the decision to publish the results.

References

  1. Hepper, F.N. Arabian and African frankincense trees. J. Egypt. Archaeol. 1969, 55, 66–72. [Google Scholar] [CrossRef]
  2. Thulin, M.; Warfa, A.M. The frankincense trees (Boswellia spp., Burseraceae) of northern Somalia and southern Arabia. Kew Bull. 1987, 42, 487–500. [Google Scholar] [CrossRef]
  3. Langenheim, J.H. Plant Resins: Chemistry, Evolution, Ecology, and Ethnobotany; Timber Press, Inc.: Portland, OR, USA, 2003. [Google Scholar]
  4. Gebrehiwot, K.; Muys, B.; Haile, M.; Mitloehner, R. Introducing Boswellia papyrifera (Del.) Hochst and its non-timber forest product, frankincense. Int. For. Rev. 2003, 5, 348–353. [Google Scholar] [CrossRef]
  5. Murthy, T.K.; Shiva, M.P. Salai Guggul from Boswellia serrata Roxb.-its exploitation and utilisation. Indian For. 1977, 103, 466–473. [Google Scholar]
  6. Moussaieff, A.; Mechoulam, R. Boswellia resin: From religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials. J. Pharm. Pharmacol. 2009, 61, 1281–1293. [Google Scholar] [CrossRef] [PubMed]
  7. Frawley, D.; Lad, V. The Yoga of Herbs: An Ayurvedic Guide to Herbal Medicine, 2nd ed.; Lotus Press: Twin Lakes, WI, USA, 2001. [Google Scholar]
  8. Mies, B.A.; Lavranos, J.J.; James, G.J. Frankincense on Soqotra island (Boswellia, Burseraceae; Yemen). Cactus Succul. J. 2000, 72, 265–278. [Google Scholar]
  9. Getahon, A. Some Common Medicinal and Poisonous Plants Used in Ethiopian Folkmedicine; Addis Abeba University: Addis Abeba, Ethiopia, 1976. [Google Scholar]
  10. Dannaway, F.R. Strange fires, weird smokes and psychoactive combustibles: Entheogens and incense in ancient traditions. J. Psychoact. Drugs 2010, 42, 485–497. [Google Scholar] [CrossRef] [PubMed]
  11. Mertens, M.; Buettner, A.; Kirchhoff, E. The volatile constituents of frankincense—A review. Flavour Fragr. J. 2009, 24, 279–300. [Google Scholar] [CrossRef]
  12. Paul, M.; Brüning, G.; Bergmann, J.; Jauch, J. A thin-layer chromatography method for the identification of three different olibanum resins (Boswellia serrata, Boswellia papyrifera and Boswellia carterii, respectively, Boswellia sacra). Phytochem. Anal. 2012, 23, 184–189. [Google Scholar] [CrossRef] [PubMed]
  13. Ren, J.; Wang, Y.-G.; Wang, A.-G.; Wu, L.-Q.; Zhang, H.-J.; Wang, W.-J.; Su, Y.-L.; Qin, H.-L. Cembranoids from the gum resin of Boswellia carterii as potential antiulcerative colitis agents. J. Nat. Prod. 2015, 78, 2322–2331. [Google Scholar] [CrossRef] [PubMed]
  14. Boscarelli, A.; Giglio, E.; Quagliata, C. Structure and conformation of incensole oxide. Acta Crystallogr. Sect. B 1981, 37, 744–746. [Google Scholar] [CrossRef] [Green Version]
  15. Hamm, S.; Bleton, J.; Connan, J.; Tchapla, A. A chemical investigation by headspace SPME and GC–MS of volatile and semi-volatile terpenes in various olibanum samples. Phytochemistry 2005, 66, 1499–1514. [Google Scholar] [CrossRef] [PubMed]
  16. Forcellese, M.L.; Nicoletti, R.; Petrossi, U. The structure of isoincensole-oxide. Tetrahedron 1972, 28, 325–331. [Google Scholar] [CrossRef]
  17. Li, F.; Xu, K.; Yuan, S.; Yan, D.; Liu, R.; Tan, J.; Zeng, G.; Zhou, Y.; Tan, G. Macrocyclic diterpenes from Boswellia carterii Birdwood (frankincense). Chin. J. Org. Chem. 2010, 30, 107–111. (In Chinese) [Google Scholar]
  18. Basar, S.; Koch, A.; König, W.A. A verticillane-type diterpene from Boswellia carterii essential oil. Flavour Fragr. J. 2001, 16, 315–318. [Google Scholar] [CrossRef]
  19. Schmidt, T.J.; Kaiser, M.; Brun, R. Complete structural assignment of serratol, a cembrane-type diterpene from Boswellia serrata, and evaluation of its antiprotozoal activity. Planta Med. 2011, 77, 849–850. [Google Scholar] [CrossRef] [PubMed]
  20. Morikawa, T.; Oominami, H.; Matsuda, H.; Yoshikawa, M. New terpenoids, olibanumols D–G, from traditional Egyptian medicine olibanum, the gum-resin of Boswellia carterii. J. Nat. Med. 2011, 65, 129–134. [Google Scholar] [CrossRef] [PubMed]
  21. Wang, Y.; Ren, J.; Wang, A.; Yang, J.; Ji, T.; Ma, Q.-G.; Tian, J.; Su, Y. Hepatoprotective prenylaromadendrane-type diterpenes from the gum resin of Boswellia carterii. J. Nat. Prod. 2013, 76, 2074–2079. [Google Scholar] [CrossRef] [PubMed]
  22. Zhang, Y.; Ning, Z.; Lu, C.; Zhao, S.; Wang, J.; Liu, B.; Xu, X.; Liu, Y. Triterpenoid resinous metabolites from the genus Boswellia: Pharmacological activities and potential species-identifying properties. Chem. Cent. J. 2013, 7, 153. [Google Scholar] [CrossRef] [PubMed]
  23. Singh, S.; Khajuria, A.; Taneja, S.C.; Johri, R.K.; Singh, J.; Qazi, G.N. Boswellic acids: A leukotriene inhibitor also effective through topical application in inflammatory disorders. Phytomedicine 2008, 15, 400–407. [Google Scholar] [CrossRef] [PubMed]
  24. Banno, N.; Akihisa, T.; Yasukawa, K.; Tokuda, H.; Tabata, K.; Nakamura, Y.; Nishimura, R.; Kimura, Y.; Suzuki, T. Anti-inflammatory activities of the triterpene acids from the resin of Boswellia carteri. J. Ethnopharmacol. 2006, 107, 249–253. [Google Scholar] [CrossRef] [PubMed]
  25. Yoshikawa, M.; Morikawa, T.; Oominami, H.; Matsuda, H. Absolute stereostructures of olibanumols A, B, C, H, I, and J from olibanum, gum-resin of Boswellia carterii, and inhibitors of nitric xxide production in lipopolysaccharide-activated mouse peritoneal macrophages. Chem. Pharm. Bull. 2009, 57, 957–964. [Google Scholar] [CrossRef] [PubMed]
  26. Morikawa, T.; Oominami, H.; Matsuda, H.; Yoshikawa, M. Four new ursane-type triterpenes, olibanumols K, L, M, and N, from traditional Egyptian medicine olibanum, the gum-resin of Boswellia carterii. Chem. Pharm. Bull. 2010, 58, 1541–1544. [Google Scholar] [CrossRef] [PubMed]
  27. Yang, J.; Ren, J.; Wang, A. Isolation, characterization, and hepatoprotective activities of terpenes from the gum resin of Boswellia carterii Birdw. Phytochem. Lett. 2018, 23, 73–77. [Google Scholar] [CrossRef]
  28. Halgren, T.A. Merck Molecular Force Field. I. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem. 1996, 17, 490–519. [Google Scholar] [CrossRef]
  29. Zhao, Y.; Truhlar, D.G. The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: Two new functionals and systematic testing of four M06-class functionals and 12 other function. Theor. Chem. Acc. 2008, 120, 215–241. [Google Scholar] [CrossRef]
  30. Marenich, A.V.; Olson, R.M.; Kelly, C.P.; Cramer, C.J.; Truhlar, D.G. Self-consistent reaction field model for aqueous and nonaqueous solutions based on accurate polarized partial charges. J. Chem. Theory Comput. 2007, 3, 2011–2033. [Google Scholar] [CrossRef] [PubMed]
  31. Setzer, W.N. Conformational analysis of macrocyclic frankincense (Boswellia) diterpenoids. J. Mol. Model. 2018, 24, 74. [Google Scholar] [CrossRef] [PubMed]
  32. Desaphy, J.; Bret, G.; Rognan, D.; Kellenberger, E. sc-PDB: A 3D-database of ligandable binding sites. Available online: http://bioinfo-pharma.u-strasbg.fr/scPDB/ (accessed on 11 September 2017).
  33. Thomsen, R.; Christensen, M.H. MolDock: A new technique for high-accuracy molecular docking. J. Med. Chem. 2006, 49, 3315–3321. [Google Scholar] [CrossRef] [PubMed]
  34. Setzer, M.S.; Sharifi-Rad, J.; Setzer, W.N. The search for herbal antibiotics: An in-silico investigation of antibacterial phytochemicals. Antibiotics 2016, 5, 30. [Google Scholar] [CrossRef] [PubMed]
  35. Kryger, G.; Silman, I.; Sussman, J.L. Structure of acetylcholinesterase complexed with E2020 (Aricept®): Implications for the design of new anti-Alzheimer drugs. Structure 1999, 7, 297–307. [Google Scholar] [CrossRef]
  36. Dabaghian, F.; Azadi, A.; Setooni, M.; Zarshenas, M.M. An overview on multi-ingredient memory enhancers and anti-Alzheimer’s formulations from traditional Persian pharmacy. Trends Pharm. Sci. 2017, 3, 215–220. [Google Scholar]
  37. Hosseinkhani, A.; Sahragard, A.; Namdari, A.; Zarshenas, M.M. Botanical sources for Alzheimer’s: A review on reports from traditional Persian medicine. Am. J. Alzheimer’s Dis. Other Dement. 2017, 32, 429–437. [Google Scholar] [CrossRef] [PubMed]
  38. Zaker, S.R.; Beheshti, S.; Aghaie, R.; Noorbakhshnia, M. Effect of olibanum on a rat model of Alzheimer’s disease induced by intracerebroventricular injection of streptozotocin. Physiol. Pharmacol. 2015, 18, 477–489. [Google Scholar]
  39. Beheshti, S.; Aghaie, R. Therapeutic effect of frankincense in a rat model of Alzheimer’s disease. Avicenna J. Phytomed. 2016, 6, 468–475. [Google Scholar] [PubMed]
  40. Mahboubi, M.; Taghizadeh, M.; Talaei, S.A.; Firozeh, S.M.T.; Rashidi, A.A.; Tamtaji, O.R. Combined administration of Melissa officinalis and Boswellia serrata extracts in an animal model of memory. Iran. J. Psychiatry Behav. Sci. 2016, 10, e681. [Google Scholar] [CrossRef] [PubMed]
  41. Tajadini, H.; Saifadini, R.; Choopani, R.; Mehrabani, M.; Kamalinejad, M.; Haghdoost, A.A. Herbal medicine Davaie Loban in mild to moderate Alzheimer’s disease: A 12-week randomized double-blind placebo-controlled clinical trial. Complement. Ther. Med. 2015, 23, 767–772. [Google Scholar] [CrossRef] [PubMed]
  42. Aghajani, M.; Taghizadeh, M.; Maghaminejad, F.; Rahmani, M. Effect of frankincense extract and lemon balm extract co-supplementation on memory of the elderly. Complement. Med. J. Fac. Nurs. Midwifery 2017, 7, 1968–1977. [Google Scholar]
  43. Ismail, S.M.; Aluru, S.; Sambasivarao, K.R.S.; Matcha, B. Antimicrobial activity of frankincense of Boswellia serrata. Int. J. Curr. Microbiol. Appl. Sci. 2014, 3, 1095–1101. [Google Scholar]
  44. Patel, N.B.; Patel, K.C. Antibacterial activity of Boswellia serrata Roxb. ex Colebr. ethanomedicinal plant against Gram negative UTI pathogens. Life Sci. Leafl. 2014, 53, 79–88. [Google Scholar]
  45. El Kichaoui, A.; Abdelmoneim, A.; Elbaba, H.; El Hindi, M. The antimicrobial effects of Boswellia carterii, Glycyrrhiza glabra and Rosmarinus officinalis some pathogenic microorganisms. IUG J. Nat. Stud. 2017, 25, 208–213. [Google Scholar]
  46. Michie, C.A.; Cooper, E. Frankincense and myrrh as remedies in children. J. R. Soc. Med. 1991, 84, 602–605. [Google Scholar] [PubMed]
  47. Abdallah, E.M.; Khalid, A.S.; Ibrahim, N. Antibacterial activity of oleo-gum resins of Commiphora molmol and Boswellia papyrifera against methicillin resistant Staphylococcus aureus (MRSA). Sci. Res. Essays 2009, 4, 351–356. [Google Scholar]
  48. Khosravi Samani, M.; Mahmoodian, H.; Moghadamnia, A.A.; Poorsattar Bejeh Mir, A.; Chitsazan, M. The effect of frankincense in the treatment of moderate plaque-induced gingivitis: A double blinded randomized clinical trial. DARU J. Pharm. Sci. 2011, 19, 288–294. [Google Scholar]
  49. Tee, W.; Lambert, J.R.; Dwyer, B. Cytotoxin production by Helicobacter pylori from patients with upper gastrointestinal-tract diseases. J. Clin. Microbiol. 1995, 33, 1203–1205. [Google Scholar] [PubMed]
  50. Lemenih, M.; Teketay, D. Frankincense and myrrh resources of Ethiopia: II. Medicinal and industrial uses. Ethiop. J. Sci. 2003, 26, 161–172. [Google Scholar]
  51. El-Mekkawy, S.; Meselhy, M.R.; Kusumoto, I.T.; Kadota, S.; Hattori, M.; Namba, T. Inhibitory effects of Egyptian folk medicines on human immunodeficiency virus (HIV) reverse transcriptase. Chem. Pharm. Bull. 1995, 43, 641–648. [Google Scholar] [CrossRef] [PubMed]
  52. Karplus, M. Vicinal proton coupling in nuclear magnetic resonance. J. Am. Chem. Soc. 1963, 85, 2870–2871. [Google Scholar] [CrossRef]
  53. Haasnoot, C.A.G.; de Leeuw, F.A.A. M.; Altona, C. The relationship between proton-proton NMR coupling constants and substituent electronegativities—I: An empirical generalization of the Karplus equation. Tetrahedron 1980, 36, 2783–2792. [Google Scholar] [CrossRef]
  54. Shen, J.; Hilgenbrink, A.R.; Xia, W.; Feng, Y.; Dimitrov, D.S.; Lockwood, M.B.; Amato, R.J.; Low, P.S. Folate receptor-β constitutes a marker for human proinflammatory monocytes. J. Leukoc. Biol. 2014, 96, 563–570. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Shen, J.; Putt, K.S.; Visscher, D.W.; Murphy, L.; Cohen, C.; Singhal, S.; Sandusky, G.; Feng, Y.; Dimitrov, D.S.; Low, P.S. Assessment of folate receptor-β expression in human neoplastic tissues. Oncotarget 2015, 6, 14700–14709. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Wibowo, A.S.; Singh, M.; Reeder, K.M.; Carter, J.J.; Kovach, A.R.; Meng, W.; Ratnam, M.; Zhang, F.; Dann, C.E. Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition. Proc. Natl. Acad. Sci. USA 2013, 110, 15180–15188. [Google Scholar] [CrossRef] [PubMed]
  57. Ernst, E. Frankincense: Systematic review. BMJ 2008, 337, a2813. [Google Scholar] [CrossRef] [PubMed]
  58. Khan, M.A.; Ali, R.; Parveen, R.; Najmi, A.K.; Ahmad, S. Pharmacological evidences for cytotoxic and antitumor properties of boswellic acids from Boswellia serrata. J. Ethnopharmacol. 2016, 191, 315–323. [Google Scholar] [CrossRef] [PubMed]
  59. Iram, F.; Khan, S.A.; Husain, A. Phytochemistry and potential therapeutic actions of Boswellic acids: A mini-review. Asian Pac. J. Trop. Biomed. 2017, 7, 513–523. [Google Scholar] [CrossRef]
  60. Al-Yasiry, A.R.M.; Kiczorowska, B. Frankincense—Therapeutic properties. Postepy Hig. Med. Dosw. 2016, 70, 380–391. [Google Scholar] [CrossRef]
  61. Popa, O.M.; Cherciu, M.; Cherciu, L.I.; Dutescu, M.I.; Bojinca, M.; Bojinca, V.; Bara, C.; Popa, L.O. ERAP1 and ERAP2 gene variations influence the risk of psoriatic arthritis in Romanian population. Arch. Immunol. Ther. Exp. 2016, 64, 123–129. [Google Scholar] [CrossRef] [PubMed]
  62. Wang, H.; Syrovets, T.; Kess, D.; Büchele, B.; Hainzl, H.; Lunov, O.; Weiss, J.M.; Scharffetter-Kochanek, K.; Simmet, T. Targeting NF-κB with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis. J. Immunol. 2009, 183, 4755–4763. [Google Scholar] [CrossRef] [PubMed]
  63. Moustafa, F.; Feldman, S.R. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol. Online J. 2014, 20, 22608. [Google Scholar] [PubMed]
  64. Kimmatkar, N.; Thawani, V.; Hingorani, L.; Khiyani, R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee—A randomized double blind placebo controlled trial. Phytomedicine 2003, 10, 3–7. [Google Scholar] [CrossRef] [PubMed]
  65. Cavaillon, J.M. Pro- versus anti-inflammatory cytokines: Myth or reality. Cell. Mol. Biol. 2001, 47, 695–702. [Google Scholar] [PubMed]
  66. Bachurin, S.O.; Bovina, E.V.; Ustyugov, A.A. Drugs in clinical trials for Alzheimer’s disease: The major trends. Med. Res. Rev. 2017, 37, 1186–1225. [Google Scholar] [CrossRef] [PubMed]
  67. Brady, N.; Poljak, A.; Jayasena, T.; Sachdev, P. Natural plant-derived acetylcholinesterase inhibitors: Relevance for Alzheimer’s disease. In Natural Products Targeting Clinically Relelvant Enzymes; Andrade, P.B., Valentão, P., Pereira, D.M., Eds.; Wiley-VCH: Weinheim, Germany, 2017; pp. 297–318. [Google Scholar]
  68. Bürkle, A.; Brabeck, C.; Diefenbach, J.; Beneke, S. The emerging role of poly(ADP-ribose) polymerase-1 in longevity. Int. J. Biochem. Cell Biol. 2005, 37, 1043–1053. [Google Scholar] [CrossRef] [PubMed]
  69. Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2007, 434, 913–917. [Google Scholar] [CrossRef] [PubMed]
  70. Ratnam, K.; Low, J.A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res. 2007, 13, 1383–1388. [Google Scholar] [CrossRef] [PubMed]
  71. Xia, W.; Low, P.S. Folate-targeted therapies for cancer. J. Med. Chem. 2010, 53, 6811–6824. [Google Scholar] [CrossRef] [PubMed]
  72. Low, P.S.; Henne, W.A.; Doorneweerd, D.D. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc. Chem. Res. 2008, 41, 120–129. [Google Scholar] [CrossRef] [PubMed]
  73. Miller, T.A.; Witter, D.J.; Belvedere, S. Histone deacetylase inhibitors. J. Med. Chem. 2003, 46, 5097–5116. [Google Scholar] [CrossRef] [PubMed]
  74. Mottamal, M.; Zheng, S.; Huang, T.L.; Wang, G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 2015, 20, 3898–3941. [Google Scholar] [CrossRef] [PubMed]
  75. Yoshida, M.; Furumai, R.; Nishiyama, M.; Komatsu, Y.; Nishino, N.; Horinouchi, S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 2001, 48, S20–S26. [Google Scholar] [CrossRef] [PubMed]
  76. Lane, A.A.; Chabner, B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27, 5459–5468. [Google Scholar] [CrossRef] [PubMed]
  77. Karpozilos, A.; Pavlidis, N. The treatment of cancer in Greek antiquity. Eur. J. Cancer 2004, 40, 2033–2040. [Google Scholar] [CrossRef] [PubMed]
  78. Hamidpour, R.; Hamidpour, S.; Hamidpour, M.; Shahlari, M. Frankincense (乳香 Rǔ Xiāng; Boswellia species): From the selection of traditional applications to the novel phytotherapy for the prevention and treatment of serious diseases. J. Tradit. Complement. Med. 2013, 3, 221–226. [Google Scholar] [CrossRef] [PubMed]
  79. Frank, M.B.; Yang, Q.; Osban, J.; Azzarello, J.T.; Saban, M.R.; Saban, R.; Ashley, R.A.; Welter, J.C.; Fung, K.M.; Lin, H.K. Frankincense oil derived from Boswellia carteri induces tumor cell specific cytotoxicity. BMC Complement. Altern. Med. 2009, 9, 6. [Google Scholar] [CrossRef] [PubMed]
  80. Forouzandeh, S.; Naghsh, N.; Salimi, S.; Jahantigh, D. Cytotoxic effect of Boswellia serrata hydroalcoholic extract on human cervical carcinoma epithelial cell line. Med. Lab. J. 2014, 8, 7–13. [Google Scholar]
  81. Hakkim, F.L.; Al-Buloshi, M.; Al-Sabahi, J. Frankincense derived heavy terpene cocktail boosting breast cancer cell (MDA-MB-231) death in vitro. Asian Pac. J. Trop. Biomed. 2015, 5, 824–828. [Google Scholar] [CrossRef]
  82. Eichhorn, T.; Greten, H.J.; Efferth, T. Molecular determinants of the response of tumor cells to boswellic acids. Pharmaceuticals 2011, 4, 1171–1182. [Google Scholar] [CrossRef]
  83. Agrawal, S.S.; Saraswati, S.; Mathur, R.; Pandey, M. Antitumor properties of Boswellic acid against Ehrlich ascites cells bearing mouse. Food Chem. Toxicol. 2011, 49, 1924–1934. [Google Scholar] [CrossRef] [PubMed]
  84. Takahashi, M.; Sung, B.; Shen, Y.; Hur, K.; Link, A.; Boland, C.R.; Aggarwal, B.B.; Goel, A. Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family. Carcinogenesis 2012, 33, 2441–2449. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Yadav, V.R.; Prasad, S.; Sung, B.; Kannappan, R.; Aggarwal, B.B. Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer. Toxins 2010, 2, 2428–2466. [Google Scholar] [CrossRef] [PubMed]
  86. Ranzato, E.; Martinotti, S.; Volante, A.; Tava, A.; Masini, M.A.; Burlando, B. The major Boswellia serrata active 3-acetyl-11-keto-β-boswellic acid strengthens interleukin-1α upregulation of matrix metalloproteinase-9 via JNK MAP kinase activation. Phytomedicine 2017, 36, 176–182. [Google Scholar] [CrossRef] [PubMed]
  87. Seckl, J.R.; Walker, B.R. Minireview: 11β-Hydroxysteroid dehydrogenase type 1—A tissue-specific amplifier of glucocorticoid action. Endocrinology 2001, 142, 1371–1376. [Google Scholar] [CrossRef] [PubMed]
  88. Morton, N.M.; Paterson, J.M.; Masuzaki, H.; Holmes, M.C.; Staels, B.; Fievet, C.; Walker, B.R.; Flier, J.S.; Mullins, J.J.; Seckl, J.R. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004, 53, 931–938. [Google Scholar] [CrossRef] [PubMed]
  89. Hosfield, D.J.; Wu, Y.; Skene, E.J.; Hilgers, M.; Jennings, A.; Snell, G.P.; Aertgeerts, K. Conformational flexibility in crystal structures of human 11β-hydroxysteroid dehydrogenase type I provide insights into glucocorticoid interconversion and enzyme regulation. J. Biol. Chem. 2005, 280, 4639–4648. [Google Scholar] [CrossRef] [PubMed]
  90. Wan, Z.K.; Chenail, E.; Xiang, J.; Li, H.Q.; Ipek, M.; Bard, J.; Svenson, K.; Mansour, T.S.; Xu, X.; Tian, X.; et al. Efficacious 11β-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model. J. Med. Chem. 2009, 52, 5449–5461. [Google Scholar] [CrossRef] [PubMed]
  91. Ahangarpour, A.; Heidari, H.; Fatemeh, R.A.A.; Pakmehr, M.; Shahbazian, H.; Ahmadi, I.; Mombeini, Z.; Mehrangiz, B.H. Effect of Boswellia serrata supplementation on blood lipid, hepatic enzymes and fructosamine levels in type2 diabetic patients. J. Diabetes Metab. Disord. 2014, 13, 29. [Google Scholar] [CrossRef] [PubMed]
  92. Khalili, N.; Fereydoonzadeh, R.; Mohtashami, R.; Mehrzadi, S.; Heydari, M.; Huseini, H.F. Silymarin, olibanum, and nettle, a mixed herbal formulation in the treatment of type II diabetes: A randomized, double-blind, placebo-controlled, clinical trial. J. Evid. Based Complement. Altern. Med. 2017, 22, 603–608. [Google Scholar] [CrossRef] [PubMed]
  93. Shehata, A.M.; Quintanilla-Fend, L.; Bettio, S.; Singh, C.B.; Ammon, H.P.T. Prevention of multiple low-dose streptozotocin (MLD-STZ) diabetes in mice by an extract from gum resin of Boswellia serrata (BE). Phytomedicine 2011, 18, 1037–1044. [Google Scholar] [CrossRef] [PubMed]
  94. Kavitha, J.V.; Rosario, J.F.; Chandran, J.; Anbu, P.; Bakkiyanathan. Hypoglycemic and other related effects of Boswellia glabra in alloxan-induced diabetic rats. Indian J. Physiol. Pharmacol. 2007, 51, 29–39. [Google Scholar] [PubMed]
  95. Abe, I.; Rohmer, M.; Prestwich, G.D. Enzymatic cyclization of squalene and oxidosqualene to sterols and triterpenes. Chem. Rev. 1993, 93, 2189–2206. [Google Scholar] [CrossRef]
  96. Nes, W.D. Biosynthesis of cholesterol and other sterols. Chem. Rev. 2011, 111, 6423–6451. [Google Scholar] [CrossRef] [PubMed]
  97. Huff, M.W.; Telford, D.E. Lord of the rings—The mechanism for oxidosqualene:lanosterol cyclase becomes crystal clear. Trends Pharmacol. Sci. 2005, 26, 335–340. [Google Scholar] [CrossRef] [PubMed]
  98. Rabelo, V.W.H.; Romeiro, N.C.; Abreu, P.A. Design strategies of oxidosqualene cyclase inhibitors: Targeting the sterol biosynthetic pathway. J. Steroid Biochem. Mol. Biol. 2017, 171, 305–317. [Google Scholar] [CrossRef] [PubMed]
  99. Lenhart, A.; Reinert, D.J.; Aebi, J.D.; Dehmlow, H.; Morand, O.H.; Schulz, G.E. Binding structures and potencies of oxidosqualene cyclase inhibitors with the homologous squalene-hopene cyclase. J. Med. Chem. 2003, 46, 2083–2092. [Google Scholar] [CrossRef] [PubMed]
Medicines 05 00096 g001 550
Figure 1. Macrocyclic diterpenoids found in Boswellia species.
Figure 1. Macrocyclic diterpenoids found in Boswellia species.
Medicines 05 00096 g001
Medicines 05 00096 g002 550
Figure 2. Cneorubenoid diterpenoids isolated from Boswellia carteri.
Figure 2. Cneorubenoid diterpenoids isolated from Boswellia carteri.
Medicines 05 00096 g002
Medicines 05 00096 g003a 550Medicines 05 00096 g003b 550Medicines 05 00096 g003c 550Medicines 05 00096 g003d 550Medicines 05 00096 g003e 550
Figure 3. Triterpenoids isolated from Boswellia species.
Figure 3. Triterpenoids isolated from Boswellia species.
Medicines 05 00096 g003aMedicines 05 00096 g003bMedicines 05 00096 g003cMedicines 05 00096 g003dMedicines 05 00096 g003e
Medicines 05 00096 g004 550
Figure 4. Lowest-energy docked pose of boscartin G with Torpedo californica acetylcholinesterase (TcAChE, PDB 1e66). (A): Ribbon structure of TcAChE with boscartin G in the active site; the co-crystallized ligand (huprene X) is shown as a green wire figure. (B): Key interactions of boscartin G with amino acids in the active site of TcAChE; hydrogen bonds are shown as blue dashed lines.
Figure 4. Lowest-energy docked pose of boscartin G with Torpedo californica acetylcholinesterase (TcAChE, PDB 1e66). (A): Ribbon structure of TcAChE with boscartin G in the active site; the co-crystallized ligand (huprene X) is shown as a green wire figure. (B): Key interactions of boscartin G with amino acids in the active site of TcAChE; hydrogen bonds are shown as blue dashed lines.
Medicines 05 00096 g004
Medicines 05 00096 g005 550
Figure 5. Boscartin A. (A): Lowest-energy docked pose of boscartin A with Torpedo californica acetylcholinesterase (PDB 2cek). (B): Calculated lowest-energy conformation of boscartin A at the M06-2X/6-31G*/SM8 level of theory [31].
Figure 5. Boscartin A. (A): Lowest-energy docked pose of boscartin A with Torpedo californica acetylcholinesterase (PDB 2cek). (B): Calculated lowest-energy conformation of boscartin A at the M06-2X/6-31G*/SM8 level of theory [31].
Medicines 05 00096 g005
Medicines 05 00096 g006 550
Figure 6. Docking of boscartin G with Helicobacter pylori peptide deformylase (HpPDF, PDB 2cek). (A): Ribbon structure of HpPDF showing boscartin G in the active site; the co-crystallized ligand, 4-{(1E)-3-oxo-3-[(2-phenylethyl)amino]prop-1-en-1-yl}-1,2-phenylene diacetate, is shown as a green stick figure. (B): Key interactions of boscartin G in the active site of HpPDF; hydrogen-bonds are shown as blue dashed lines. (C): Conformation of boscartin G docked to HpPDF. (D): Lowest-energy conformation of boscartin G determined by density functional calculations (M06-2X/6-31G*/SM8) [31].
Figure 6. Docking of boscartin G with Helicobacter pylori peptide deformylase (HpPDF, PDB 2cek). (A): Ribbon structure of HpPDF showing boscartin G in the active site; the co-crystallized ligand, 4-{(1E)-3-oxo-3-[(2-phenylethyl)amino]prop-1-en-1-yl}-1,2-phenylene diacetate, is shown as a green stick figure. (B): Key interactions of boscartin G in the active site of HpPDF; hydrogen-bonds are shown as blue dashed lines. (C): Conformation of boscartin G docked to HpPDF. (D): Lowest-energy conformation of boscartin G determined by density functional calculations (M06-2X/6-31G*/SM8) [31].
Medicines 05 00096 g006
Medicines 05 00096 g007a 550Medicines 05 00096 g007b 550
Figure 7. Molecular docking of incensole oxide acetate with HIV-1 reverse transcriptase. (A): Ribbon structure of HIV1-RT (PDB 3mee) showing incensole oxide acetate in the active site. (B): Key interactions of incensole oxide acetate in the active site of HIV1-RT (PDB 3mee). (C): Key interactions of incensole oxide acetate in the active site of HIV1-RT (PDB 3lal). (D): Key interactions of incensole oxide acetate in the active site of HIV1-RT (PDB 3t19).
Figure 7. Molecular docking of incensole oxide acetate with HIV-1 reverse transcriptase. (A): Ribbon structure of HIV1-RT (PDB 3mee) showing incensole oxide acetate in the active site. (B): Key interactions of incensole oxide acetate in the active site of HIV1-RT (PDB 3mee). (C): Key interactions of incensole oxide acetate in the active site of HIV1-RT (PDB 3lal). (D): Key interactions of incensole oxide acetate in the active site of HIV1-RT (PDB 3t19).
Medicines 05 00096 g007aMedicines 05 00096 g007b
Medicines 05 00096 g008 550
Figure 8. Bacillus anthracis nucleotide adenylyltransferase (BaNadD, PDB 3hfj). (A): Lowest-energy docked poses of boscartol E (magenta) and boscartol I (green) in the active site of the dimeric enzyme. (B): Boscartol I in the hydrophobic pocket formed at the interface of the two protein monomers.
Figure 8. Bacillus anthracis nucleotide adenylyltransferase (BaNadD, PDB 3hfj). (A): Lowest-energy docked poses of boscartol E (magenta) and boscartol I (green) in the active site of the dimeric enzyme. (B): Boscartol I in the hydrophobic pocket formed at the interface of the two protein monomers.
Medicines 05 00096 g008
Medicines 05 00096 g009 550
Figure 9. Human folate receptor β (HsFRβ, PDB 4kn1). (A): Ribbon structure of protein showed the docked poses of boscartin A (yellow) and boscartin B (purple). (B): Lowest-energy docked pose of boscartin A in the binding site of HsFRβ. Hydrogen-bonds are shown as blue dashed lines.
Figure 9. Human folate receptor β (HsFRβ, PDB 4kn1). (A): Ribbon structure of protein showed the docked poses of boscartin A (yellow) and boscartin B (purple). (B): Lowest-energy docked pose of boscartin A in the binding site of HsFRβ. Hydrogen-bonds are shown as blue dashed lines.
Medicines 05 00096 g009
Medicines 05 00096 g010 550
Figure 10. Lowest-energy docking pose of olibanumol J with Staphylococcus aureus multidrug binding protein (SaQacR, PDB 3bti). (A): Ribbon structure of SaQacR showing olibanumol J (Edock = −132.6 kJ/mol) in the active site. The co-crystallized ligand, berberine (Edock = −113.8 kJ/mol), is shown as a green wire structure. (B): Key interactions of olibanumol J in the active site of SaQacR. The hydrogen-bond is indicated by a blue dashed line.
Figure 10. Lowest-energy docking pose of olibanumol J with Staphylococcus aureus multidrug binding protein (SaQacR, PDB 3bti). (A): Ribbon structure of SaQacR showing olibanumol J (Edock = −132.6 kJ/mol) in the active site. The co-crystallized ligand, berberine (Edock = −113.8 kJ/mol), is shown as a green wire structure. (B): Key interactions of olibanumol J in the active site of SaQacR. The hydrogen-bond is indicated by a blue dashed line.
Medicines 05 00096 g010
Medicines 05 00096 g011 550
Figure 11. Enterobacter cloacae pentaerythritol tetranitrate reductase (EcPETNR, PDB 2aba). (A): Ribbon structure of EcPETNR with docked dammarane triterpenoids (stick figures). The riboflavin monophosphate cofactor is shown as a space-filling model. (B): Lowest-energy docked pose of 3β-acetoxy-20S,24S-dihydroxydammar-25-ene. Hydrogen-bonding interactions are indicated with blue dashed lines.
Figure 11. Enterobacter cloacae pentaerythritol tetranitrate reductase (EcPETNR, PDB 2aba). (A): Ribbon structure of EcPETNR with docked dammarane triterpenoids (stick figures). The riboflavin monophosphate cofactor is shown as a space-filling model. (B): Lowest-energy docked pose of 3β-acetoxy-20S,24S-dihydroxydammar-25-ene. Hydrogen-bonding interactions are indicated with blue dashed lines.
Medicines 05 00096 g011
Medicines 05 00096 g012a 550Medicines 05 00096 g012b 550
Figure 12. Lowest-energy docked poses of β-boswellic acid derivatives with Torpedo californica acetylcholinesterase (TcAChE, PDB 3i6m). (A): Ribbon structure with docked ligands, β-boswellic acid (brown), 11-keto-β-boswellic acid (magenta), 11-ethoxy-β-boswellic acid (yellow), 3-acetyl-β-boswellic acid (red), and 3-acetyl-11-keto-β-boswellic acid (aqua). (B): Molecular environment of docked β-boswellic acid in the active site of TcAChE. (C): Molecular environment of docked 3-acetyl-11-keto-β-boswellic acid in the active site of TcAChE.
Figure 12. Lowest-energy docked poses of β-boswellic acid derivatives with Torpedo californica acetylcholinesterase (TcAChE, PDB 3i6m). (A): Ribbon structure with docked ligands, β-boswellic acid (brown), 11-keto-β-boswellic acid (magenta), 11-ethoxy-β-boswellic acid (yellow), 3-acetyl-β-boswellic acid (red), and 3-acetyl-11-keto-β-boswellic acid (aqua). (B): Molecular environment of docked β-boswellic acid in the active site of TcAChE. (C): Molecular environment of docked 3-acetyl-11-keto-β-boswellic acid in the active site of TcAChE.
Medicines 05 00096 g012aMedicines 05 00096 g012b
Medicines 05 00096 g013 550
Figure 13. Guinea pig 11β-hydroxysteroid dehydrogenase type 1 (Cp11β-HSD, PDB 3lz6). (A): Lowest-energy docked poses of 3β-acetoxy-20S,24R-dihydroxydammar-25-ene (magenta), 3β-acetoxydammar-24-ene-16β,20R-diol (green), dammarenediol II acetate (yellow), and isofouquieryl acetate (blue) with Cp11β-HSD. The NADPH cofactor is shown as a space-filling model. (B): Isofouqueryl acetate in the active site of Cp11β-HSD showing the molecular environment.
Figure 13. Guinea pig 11β-hydroxysteroid dehydrogenase type 1 (Cp11β-HSD, PDB 3lz6). (A): Lowest-energy docked poses of 3β-acetoxy-20S,24R-dihydroxydammar-25-ene (magenta), 3β-acetoxydammar-24-ene-16β,20R-diol (green), dammarenediol II acetate (yellow), and isofouquieryl acetate (blue) with Cp11β-HSD. The NADPH cofactor is shown as a space-filling model. (B): Isofouqueryl acetate in the active site of Cp11β-HSD showing the molecular environment.
Medicines 05 00096 g013
Medicines 05 00096 g014 550
Figure 14. Alicyclobacillus acidocaldarius oxidosqualene cyclase (AaOSC, PDB 1h36). (A): Lowest energy docked poses of ocotillyl acetate (magenta), 3β-acetoxydammar-24-ene-16β,20R-diol (green), and dammarenediol II acetate (yellow) with AaOSC. (B): Molecular environment of docked ocotillyl acetate in the active site of AaOSC.
Figure 14. Alicyclobacillus acidocaldarius oxidosqualene cyclase (AaOSC, PDB 1h36). (A): Lowest energy docked poses of ocotillyl acetate (magenta), 3β-acetoxydammar-24-ene-16β,20R-diol (green), and dammarenediol II acetate (yellow) with AaOSC. (B): Molecular environment of docked ocotillyl acetate in the active site of AaOSC.
Medicines 05 00096 g014
Table
Table 1. Protein targets with the most exothermic docking energies (Edock, kJ/mol) for Boswellia cembranoid ligands.
Table 1. Protein targets with the most exothermic docking energies (Edock, kJ/mol) for Boswellia cembranoid ligands.
LigandPDB aEdockTarget Protein
Boscartin A1e66−119.7Torpedo californica acetylcholinesterase (TcAChE)
2cek−123.7Torpedo californica acetylcholinesterase (TcAChE)
4bdt−113.5human acetylcholinesterase (HsAChE)
−79.2Median docking energy
Boscartin B1h0g−107.8Serratia marcescens chitinase B (SmChiB)
2ew5−104.6Helicobacter pylori peptide deformylase (HpPDF)
3tfu−107.5Mycobacterium tuberculosis 7,8-diaminopelargonic acid synthase (MtBioA)
3v0o−110.4human fucosylgalactoside α N-acetylgalactosaminyltransferase (HsGTA)
−80.5Median docking energy
Boscartin C1ahg−112.5Escherichia coli aspartate aminotransferase (EcAspTA)
1fv0−108.2Daboia russelii (Russell’s viper) phospholipase A2 (DrPLA2)
1q83−110.4murine acetylcholinesterase (MmAChE)
4g1n−106.5human pyruvate kinase isozyme M2 (HsPKM2)
−91.2Median docking energy
Boscartin D1ahg−114.4Escherichia coli aspartate aminotransferase (EcAspTA)
1xzq−106.3Thermotoga maritima GTP-binding protein TrmE (TmTrmE)
2cek−115.3Torpedo californica acetylcholinesterase (TcAChE)
−82.0Median docking energy
Boscartin E1ahg−110.4Escherichia coli aspartate aminotransferase (EcAspTA)
1e66−111.7Torpedo californica acetylcholinesterase (TcAChE)
2ew5−107.5Helicobacter pylori peptide deformylase (HpPDF)
−68.4Median docking energy
Boscartin F2ew5−109.5Helicobacter pylori peptide deformylase (HpPDF)
3i6m−107.3Torpedo californica acetylcholinesterase (TcAChE)
4g1n−108.5human pyruvate kinase isozyme M2 (HsPKM2)
−82.9Median docking energy
Boscartin G1e66−126.4Torpedo californica acetylcholinesterase (TcAChE)
2cek−116.8Torpedo californica acetylcholinesterase (TcAChE)
4bdt−118.7human acetylcholinesterase (HsAChE)
−89.9Median docking energy
Boscartin H1fv0−106.9Daboia russelii (Russell’s viper) phospholipase A2 (DrPLA2)
1w1t−106.0Serratia marcescens chitinase B (SmChiB)
2gyw−105.9murine acetylcholinesterase (MmAChE)
3v0o−109.3human fucosylgalactoside α N-acetylgalactosaminyltransferase (HsGTA)
−88.4Median docking energy
Incensole2cek−111.9Torpedo californica acetylcholinesterase (TcAChE)
3ugr−109.7human aldo-keto reductase 1C3 (HsAKR1C3)
1h0g−102.4Serratia marcescens chitinase B (SmChiB)
−78.1Median docking energy
Incensole acetate1ahg−106.9Escherichia coli aspartate aminotransferase (EcAspTA)
3jun−103.7Burkholderia cepacia phenazine biosynthesis protein A/B (BcPhzA/B)
−69.5Median docking energy
Incensole oxide1ahg−108.6Escherichia coli aspartate aminotransferase (EcAspTA)
2cek−103.1Torpedo californica acetylcholinesterase (TcAChE)
3jup−103.5Burkholderia cepacia phenazine biosynthesis protein A/B (BcPhzA/B)
3mee−106.7HIV-1 reverse transcriptase (HIV-1 RT)
−74.6Median docking energy
Incensole oxide acetate1ahg−119.0Escherichia coli aspartate aminotransferase (EcAspTA)
1q83−109.6murine acetylcholinesterase (MmAChE)
2cek−110.4Torpedo californica acetylcholinesterase (TcAChE)
3i6m−114.3Torpedo californica acetylcholinesterase (TcAChE)
3mee−113.5HIV-1 reverse transcriptase (HIV-1 RT)
−91.9Median docking energy
Isoincensole oxide3jup−103.3Burkholderia cepacia phenazine biosynthesis protein A/B (BcPhzA/B)
−80.5Median docking energy
Isoincensolol1fv0−108.2Daboia russelii (Russell’s viper) phospholipase A2 (DrPLA2)
1jus−107.9Staphylococcus aureus multidrug binding protein (SaQacR)
2qp4−102.2human dehydroepiandrosterone sulfotransferase (HsSULT2A1)
−74.0Median docking energy
Serratol1e66−104.1Torpedo californica acetylcholinesterase (TcAChE)
2cek−106.1Torpedo californica acetylcholinesterase (TcAChE)
2ew5−103.2Helicobacter pylori peptide deformylase (HpPDF)
4bdt−103.0human acetylcholinesterase (HsAChE)
−78.1Median docking energy
Verticillatriene1w4l−104.3Torpedo californica acetylcholinesterase (TcAChE)
3i6m−100.8Torpedo californica acetylcholinesterase (TcAChE)
3i6z−103.2Torpedo californica acetylcholinesterase (TcAChE)
−63.6Median docking energy
a PDB: Protein Data Bank code.
Table
Table 2. MolDock molecular docking energies (kJ/mol) of Boswellia cembranoids with acetylcholinesterase protein targets. a
Table 2. MolDock molecular docking energies (kJ/mol) of Boswellia cembranoids with acetylcholinesterase protein targets. a
LigandTcAChETcAChETcAChETcAChETcAChETcAChEMmAChEMmAChEHsAChE
1e661h221w4l2cek3i6m3i6z1q832gyw4bdt
Boscartin A−119.7−98.4−99.5−123.7−98.2−100.6−95.9−101.4−113.5
Boscartin B−95.1−98.8−92.5−106.3−99.2−94.5−94.3−85.8−106.3
Boscartin C−87.7−90.8−94.7−96.9−104.1−94.2−110.4−94.0−86.6
Boscartin D−99.7−102.8−93.1−115.3−103.7−93.9−92.5−93.6−90.2
Boscartin E−111.7−96.5−94.5−108.7−95.5−92.9−86.0−94.8−90.6
Boscartin F−93.2−97.0−98.5−104.8−107.3−95.8−101.1−82.4−77.3
Boscartin G−126.4−99.4−94.5−116.8−101.5−95.6−111.1−94.1−118.7
Boscartin H−100.1−106.3−103.6−105.6−103.0−104.2−98.8−105.9−97.8
Incensole−89.7−92.1−89.5−111.9−94.1−89.6−90.3−87.7−53.4
Incensole acetate−88.6−97.2−102.8−102.5−102.3−101.7−87.5−85.0−42.3
Incensole oxide−89.6−93.2−92.7−103.1−96.9−89.3−101.9−95.5−93.5
Incensole oxide acetate−109.8−98.7−96.8−110.4−114.3−95.8−109.6−97.7−102.6
Isoincensole oxide−92.9−98.9−96.4−103.6−98.1−89.9−89.9−90.3−94.1
Isoincensolol−88.5−99.5−92.4−101.5−98.3−91.2−77.0−80.4−73.6
Serratol−104.1−95.7−92.2−106.1−94.5−88.1−96.4−89.3−104.0
Verticillatriene−82.5−91.2−104.3−85.3−100.8−103.2−73.9−98.1−61.2
a TcAChE = Torpedo californica acetylcholinesterase. MmAChE = Mus musculus (murine) acetylcholinesterase. HsAChE = human acetylcholinesterase.
Table
Table 3. MolDock molecular docking energies (kJ/mol) of Boswellia cembranoids with bacterial target proteins. a
Table 3. MolDock molecular docking energies (kJ/mol) of Boswellia cembranoids with bacterial target proteins. a
LigandEcAspTASmChiBSmChiBSmChiBSaQacRSaQacRSaQacRSaQacRHpPDFBcPhzA/BBcPhzA/BMtBioA
1ahg1h0g1w1t3wd21jus1rpw3br23bti2ew53jun3jup3tfu
Boscartin A−116.9−93.6−99.4−96.3−99.4−104.1−94.9−95.7−101.8−100.3−107.8−104.9
Boscartin B−98.2−107.8−103.7−91.5−98.1−106.5−94.7−96.5−104.6−98.4−93.9−107.5
Boscartin C−112.5−96.3−97.3−90.6−100.0−98.5−98.4−102.3−106.2−99.3−106.4−100.4
Boscartin D−114.4−99.7−105.3−91.5−95.2−106.2−100.1−96.3−104.9−98.0−95.8−99.3
Boscartin E−110.4−101.0−105.9−105.4−99.2−101.3−95.3−95.3−107.5−84.7−96.7−107.7
Boscartin F−99.7−97.3−103.7−89.9−101.0−95.7−94.4−85.2−109.5−87.7−98.0−95.1
Boscartin G−105.5−90.8−93.0−93.8−95.1−98.2−92.2−88.7−112.7−95.4−92.6−108.5
Boscartin H−104.1−103.6−106.0−104.4−97.2−98.8−97.4−94.5−100.9−93.4−101.5−99.5
Incensole−104.3−102.4−101.1−96.2−85.0−96.3−90.7−95.0−94.0−92.9−93.0−95.7
Incensole acetate−109.9−102.3−96.2−98.1−96.6−104.5−96.1−98.8−96.2−103.7−91.5−96.2
Incensole oxide−108.6−92.0−93.5−90.3−97.4−99.8−94.2−95.6−101.4−97.1−103.5−103.5
Incensole oxide acetate−119.0−101.1−98.9−96.4−96.7−98.7−99.2−100.0−106.9−105.5−99.4−100.0
Isoincensole oxide−96.2−87.6−93.5−89.9−98.5−97.5−98.5−92.7−88.9−87.5−103.3−91.2
Isoincensolol−87.3−91.2−88.9−87.9−107.9−90.0−99.6−87.8−99.7−91.5−100.0−95.2
Serratol−90.2−90.1−89.9−82.2−90.1−91.4−97.6−89.1−103.2−87.4−92.7−93.4
Verticillatriene−74.0−69.5−69.0−69.5−81.2−87.2−85.5−78.5−77.3−76.5−89.9−84.4
a EcAspTA = Escherichia coli aspartate transaminase. SmChiB = Serratia marcescens chitinase. SaQacR = Staphylococcus aureus multidrug binding protein. HpPDF = Helicobacter pylori peptide deformylase. BcPhzA/B = Burkholderia cepacia phenazine biosynthesis protein A/B. MtBioA = Mycobacterium tuberculosis 7,8-diaminopelargonic acid synthase.
Table
Table 4. MolDock molecular docking energies (kJ/mol) of Boswellia cembranoids with human immunodeficiency virus type 1 reverse transcriptase (HIV1-RT).
Table 4. MolDock molecular docking energies (kJ/mol) of Boswellia cembranoids with human immunodeficiency virus type 1 reverse transcriptase (HIV1-RT).
Ligand1eet2hnz3irx3is93mee3lal3t19
Boscartin A−99.1−101.7−96.8−93.8−96.0−69.4−75.4
Boscartin B−94.1−98.5−100.2−94.7−95.6−72.2−97.8
Boscartin C−104.2−91.5−97.0−101.3−100.5−87.8−84.0
Boscartin D−89.2−100.5−97.1−97.1−96.4−78.7−83.2
Boscartin E−97.2−100.6−91.7−97.0−89.4−60.8−72.0
Boscartin F−88.9−93.8−98.1−98.1−95.1−88.1−69.4
Boscartin G−92.8−88.7−97.6−95.4−113.8+9.3−82.3
Boscartin H−98.2−90.4−96.9−97.1−98.2−86.9−56.2
Incensole−83.8−101.5−88.8−88.3−86.8−84.0−94.7
Incensole acetate−95.6−92.6−97.9−97.0−84.6−95.9−91.6
Incensole oxide−105.1−93.2−94.9−98.7−106.7−81.7−79.0
Incensole oxide acetate−107.2−84.5−106.8−106.2−113.5−87.8−87.1
Isoincensole oxide−97.8−86.5−89.4−90.2−98.7−77.5−57.7
Isoincensolol−95.2−85.6−98.2−85.4−85.9−70.6−72.5
Serratol−90.4−87.9−86.8−89.3−90.1−56.0−48.9
Verticillatriene−81.6−67.1−78.4−81.0−82.5−76.9−25.5
Table
Table 5. Protein targets with the most exothermic docking energies (Edock, kJ/mol) for Boswellia cneorubenoid ligands.
Table 5. Protein targets with the most exothermic docking energies (Edock, kJ/mol) for Boswellia cneorubenoid ligands.
LigandPDB aEdockTarget Protein
Boscartol A3hfj−124.2Bacillus anthracis nucleotide adenyltransferase (BaNadD)
4kn0−125.6human folate receptor β (HsFRβ)
4kn1−127.5human folate receptor β (HsFRβ)
−89.7Median docking energy
Boscartol B3hfj−124.2Bacillus anthracis nucleotide adenyltransferase (BaNadD)
4kn0−127.8human folate receptor β (HsFRβ)
4kn1−126.8human folate receptor β (HsFRβ)
−91.6Median docking energy
Boscartol C3bt9−120.2Staphylococcus aureus multidrug binding protein (SaQacR)
−85.8Median docking energy
(15R)-Boscartol D2cek−120.9Torpedo californica acetylcholine esterase (TcAChE)
3bt9−122.7Staphylococcus aureus multidrug binding protein (SaQacR)
3lal−125.5HIV-1 reverse transcriptase
3t19−123.1HIV-1 reverse transcriptase
−87.6Median docking energy
(15S)-Boscartol D3lal−120.6HIV-1 reverse transcriptase
−81.8Median docking energy
Boscartol E1s9d−125.9bovine guanine nucleotide exchange factor (BtGEF)
3hjf−135.1Bacillus anthracis nucleotide adenyltransferase (BaNadD)
4b80−124.1murine acetylcholinesterase (MmAChE)
4kn0−124.2human folate receptor β (HsFRβ)
−85.0Median docking energy
Boscartol F1s9d−124.5bovine guanine nucleotide exchange factor (BtGEF)
3hfj−123.1Bacillus anthracis nucleotide adenyltransferase (BaNadD)
4kn1−122.3human folate receptor β (HsFRβ)
−84.6Median docking energy
Boscartol G3hfj−125.8Bacillus anthracis nucleotide adenylyltransferase (BaNadD)
−80.3Median docking energy
Boscartol H1dx4−123.6Drosophila melanogaster acetylcholine esterase (DmAChE)
3bt9−122.0Staphylococcus aureus multidrug binding protein (SaQacR)
3hfj−127.9Bacillus anthracis nucleotide adenyltransferase (BaNadD)
4kn0−124.6human folate receptor β (HsFRβ)
−85.9Median docking energy
Boscartol I3hfj−133.8Bacillus anthracis nucleotide adenyltransferase (BaNadD)
3p2v−121.1human aldose reductase (HsAR)
4kn0−127.3human folate receptor β (HsFRβ)
−91.4Median docking energy
Olibanumol D4kn1−120.6human folate receptor β (HsFRβ)
−78.4Median docking energy
a PDB: Protein Data Bank code.
Table
Table 6. Protein targets with the most exothermic docking energies (Edock, kJ/mol) for Boswellia triterpenoid ligands.
Table 6. Protein targets with the most exothermic docking energies (Edock, kJ/mol) for Boswellia triterpenoid ligands.
LigandPDB aEdockTarget
(20S)-3,7-Dioxotirucalla-8,24-dien-21-oic acid3l3m−141.8Human poly(ADP-ribose) polymerase-1 (HsPARP-1) (anticancer target)
3ua9−140.3Human tankyrase-2 (HsTANK2) = human poly(ADP-ribose) polymerase-5b (HsPARP-5b) (antitumor target)
3g49−132.4Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1) (diabetes target)
2b03−127.4Porcine pancreatic phospholipase A2 (SsPLA2) (anti-inflammatory target)
−91.3Median docking energy
11-Ethoxy-β-boswellic acid3i6m−124.6Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
−63.0Median docking energy
11-Keto-β-boswellic acid4b84−125.3Murine acetylcholinesterase (MmAChE) (Alzheimer’s target)
3i6m−120.8Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
−59.9Median docking energy
12-Ursen-3,11-dione1h22−118.8Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
−64.2Median docking energy
12-Ursen-3,24-diol1h22−123.8Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
+17.4Median docking energy
2,3-Dihydroxy-12-ursen-24-oic acid4b84−128.0Murine acetylcholinesterase (MmAChE) (Alzheimer’s target)
+16.2Median docking energy
20,22-Epoxytirucall-24-en-3-one3l3m−133.5Human poly(ADP-ribose) polymerase-1 (HsPARP-1) (anticancer target)
3g49−125.0Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1) (diabetes target)
−88.9Median docking energy
24-Nor-3,12-ursadien-11-one1h22−121.0Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
4b84−120.9Murine acetylcholinesterase (MmAChE) (Alzheimer’s target)
+30.9Median docking energy
24-Nor-3,9(11),12-oleanatriene3lz6−112.6Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1) (diabetes target)
−31.2Median docking energy
24-Nor-3,9(11),12-ursatriene1h22−118.4Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
+15.1Median docking energy
3-Acetoxy-12,20(29)-lupadien-24-oic acid1uk1−118.4Human poly(ADP-ribose) polymerase-1 (HsPARP-1) (anticancer target)
3bti−117.9Staphylococcus aureus multidrug binding protein (SaQacR)
+16.4Median docking energy
3-Acetoxy-20(29)-lupen-24-oic acid (= 3-Acetyl lupeolic acid)1cgl−117.5Human fibroblast collagenase (HsMMP-1) (arthritis target)
+8.0Median docking energy
3β-Acetoxy-20S,24R-dihydroxydammar-25-ene b2aba−144.7Enterobacter cloacae pentaerythritol tetranitrate reductase (EcPETNR) (antibacterial target)
3lz6−141.8Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1) (diabetes target)
1h36−136.4Alicyclobacillus acidocardarius oxidosqualene cyclase (Aa OSC) (cholesterol-lowering)
−64.6Median docking energy
3β-Acetoxy-20S,24S-dihydroxydammar-25-ene b2aba−149.9Enterobacter cloacae pentaerythritol tetranitrate reductase (EcPETNR) (antibacterial target)
3g49−139.7Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1) (diabetes target)
3lz6−136.2Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1) (diabetes target)
3tfu−134.5Mycobacterium tuberculosis 7,8-diaminopelargonic acid synthase (MtBioA)
−73.7Median docking energy
3-Acetoxy-5,12-ursadien-24-oic acid3i6m−131.7Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
−66.7Median docking energy
3-Acetyl-11-keto-β-boswellic acid3i6m−129.7Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
−70.7Median docking energy
3-Acetyl-11α-methoxy-β-boswellic_acid3i6m−129.0Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
−72.2Median docking energy
3-Acetyl-9,11-dehydro-β-boswellic_acid3i6m−124.0Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
−64.4Median docking energy
3-Acetyl-α-boswellic acid2b03−112.7Porcine pancreatic phospholipase A2 (SsPLA2) (anti-inflammatory target)
−64.8Median docking energy
3-Acetyl-β-boswellic acid3i6m−128.3Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
−71.5Median docking energy
3-Hydroxy-20(29)-lupen-24-oic acid (= Lupeolic acid)3bt9−119.3Staphylococcus aureus multidrug binding protein (SaQacR)
−55.8Median docking energy
3-Oxotirucalla-7,9(11),24-trien-21-oic acid3ua9−151.0Human tankyrase-2 (HsTANK2) = human poly(ADP-ribose) polymerase-5b (HsPARP-5b) (antitumor target)
3l3m−137.6Human poly(ADP-ribose) polymerase-1 (HsPARP-1) (anticancer target)
3h6k−130.9Human 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) (diabetes target)
1w6j−127.5Human oxidosqualene cyclase (HsOSC) (hypercholesterolemia target)
3bt9−127.1Staphylococcus aureus multidrug binding protein (SaQacR)
−96.8Median docking energy
3β-Hydroxytirucalla-8,24-dien-21-oic acid3ua9−144.5Human tankyrase-2 (HsTANK2) = human poly(ADP-ribose) polymerase-5b (HsPARP-5b) (antitumor target)
3l3m−133.0Human poly(ADP-ribose) polymerase-1 (HsPARP-1) (anticancer target)
3g49−132.3Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1) (diabetes target)
2ilt−129.1Human 11β-hydroxysteroid-dehydrogenase (Hs11β-HSDH) (diabetes target)
4krs−127.7Human tankyrase-1 (HsTANK1) (anticancer target)
4l0i−127.3Human tankyrase-2 (HsTANK2) (anticancer target)
−85.6Median docking energy
3α-Acetoxytirucalla-7,24-dien-21-oic acid3ua9−147.1Human tankyrase-2 (HsTANK2) = human poly(ADP-ribose) polymerase-5b (HsPARP-5b) (antitumor target)
4krs−134.1Human tankyrase-1 (HsTANK1) (anticancer target)
1cgl−129.9Human fibroblast collagenase (HsMMP-1) (arthritis target)
4gv0−128.4Human poly(ADP-ribose) polymerase-1 (HsPARP-1) (anticancer target)
4l0i−128.4Human tankyrase-2 (HsTANK2) (anticancer target)
3lep−126.8Human aldose reductase (HsAR) (diabetes target)
−102.1Median docking energy
3α-Hydroxytirucalla-7,24-dien-21-oic acid3ua9−154.3Human tankyrase-2 (HsTANK2) = human poly(ADP-ribose) polymerase-5b (HsPARP-5b) (antitumor target)
3g49−128.9Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1) (diabetes target)
3l3m−126.7Human poly(ADP-ribose) polymerase-1 (HsPARP-1) (anticancer target)
3tfu−126.4Mycobacterium tuberculosis 7,8-diaminopelargonic acid synthase (MtBioA)
−88.7Median docking energy
3β-Acetoxydammar-24-ene-16β,20R-diol3lz6−149.6Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1) (diabetes target)
2aba−141.1Enterobacter cloacae pentaerythritol tetranitrate reductase (EcPETNR) (antibacterial target)
1h36−139.2Alicyclobacillus acidocardarius oxidosqualene cyclase (AaOSC) (cholesterol-lowering)
1s0x−131.2Human retinoic acid-related orphan receptor α (HsRORα) (may regulate lipid metabolism)
−54.0Median docking energy
3β-Acetoxylup-20(29)-en-11β-ol1uk1−121.9Human poly(ADP-ribose) polymerase-1 (HsPARP-1) (anticancer target)
−50.4Median docking energy
4,23-Dihydroburic acid1h22−135.8Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
4b84−127.8Murine acetylcholinesterase (MmAChE) (Alzheimer’s target)
1jtx−125.1Staphylococcus aureus multidrug binding protein (SaQacR)
+11.7Median docking energy
6,7-Epoxy-9(11)-oleanen-3-ol4hai−111.6Human soluble epoxide hydrolase (HsEPHX2) (anti-inflammatory target)
−60.7Median docking energy
6,7-Epoxy-9(11)-oleanen-3-one1ry0−113.7Human prostaglandin F synthase (HsPGFS) (hypertension target)
−49.1Median docking energy
9,11-Dehydro-β-boswellic acid1qvu−114.3Staphylococcus aureus multidrug binding protein (SaQacR)
−60.8Median docking energy
Boscartene L3l3m−131.0Human poly(ADP-ribose) polymerase-1 (HsPARP-1) (anticancer target)
−87.6Median docking energy
Boscartene M3l3m−133.7Human poly(ADP-ribose) polymerase-1 (HsPARP-1) (anticancer target)
−89.4Median docking energy
Boscartene N3ua9−157.2Human tankyrase-2 (HsTANK2) = human poly(ADP-ribose) polymerase-5b (HsPARP-5b) (antitumor target)
3bt9−136.7Staphylococcus aureus multidrug binding protein (SaQacR)
3l3m−133.3Human poly(ADP-ribose) polymerase-1 (HsPARP-1) (anticancer target)
1xl5−125.2HIV-1 protease
−95.1Median docking energy
Dammarenediol II1w6k−135.1Human oxidosqualene cyclase (HsOSC) (hypercholesterolemia target)
3lz6−134.6Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1) (diabetes target)
1h36−129.2Alicyclobacillus acidocardarius oxidosqualene cyclase (AaOSC) (cholesterol-lowering)
−72.1Median docking energy
Dammarenediol II acetate3lz6−142.8Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1) (diabetes target)
1h36−138.9Alicyclobacillus acidocardarius oxidosqualene cyclase (AaOSC) (cholesterol-lowering)
2aba−136.4Enterobacter cloacae pentaerythritol tetranitrate reductase (EcNETNR) (antibacterial target)
4kn0−132.3Human folate receptor β (HsFRβ) (anticancer target)
−77.7Median docking energy
Eupha-2,8,22-triene-20,24R-diol b3l3m−139.8Human poly(ADP-ribose) polymerase-1 (HsPARP-1) (anticancer target)
3ua9−135.3Human tankyrase-2 (HsTANK2) = human poly(ADP-ribose) polymerase-5b (HsPARP-5b) (antitumor target)
4dbs−124.0Human estrogenic 17β-hydroxysteroid dehydrogenase (17β-HSD1)
−94.9Median docking energy
Eupha-2,8,22-triene-20,24S-diol b1uk1−137.6Human poly(ADP-ribose) polymerase-1 (HsPARP-1) (anticancer target)
3ua9−135.8Human tankyrase-2 (HsTANK2) = human poly(ADP-ribose) polymerase-5b (HsPARP-5b) (antitumor target)
4dbs−127.4Human estrogenic 17β-hydroxysteroid dehydrogenase (17β-HSD1)
−85.1Median docking energy
Isofouquierol3lz6−134.1Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1) (diabetes target)
2aba−131.3Enterobacter cloacae pentaerythritol tetranitrate reductase (EcPETNR) (antibacterial target)
4kn0−130.4Human folate receptor β (HsFRβ) (anticancer target)
−83.2Median docking energy
Isofouquieryl acetate3lz6−150.1Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1) (diabetes target)
2aba−137.9Enterobacter cloacae pentaerythritol tetranitrate reductase (EcPETNR) (antibacterial target)
4kn0−137.0Human folate receptor β (HsFRβ) (anticancer target)
1s0x−135.7Human retinoic acid-related orphan receptor α (HsRORα) (may regulate lipid metabolism)
1h35−135.5Alicyclobacillus acidocardarius oxidosqualene cyclase (AaOSC) (cholesterol-lowering)
2w4q−132.7Human zinc-binding alcohol dehydrogenase 1 (HsZADH1)
3g49−132.4Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1) (diabetes target)
2zxm−131.0Rat vitamin D receptor (RnVDR) (target for psoriasis)
−79.3Median docking energy
Lup-20(29)-ene-2α,3β-diol1xu9−112.5Human 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) (diabetes target)
3wd2−112.4Serratia marcescens chitinase B (SmChiB)
1xl5−112.2HIV-1 protease
−62.2Median docking energy
Neoilexonol1h22−118.2Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
−66.7Median docking energy
Neoilexonyl acetate2ilt−118.8Human 11β-hydroxysteroid-dehydrogenase (Hs11β-HSDH) (diabetes target)
4b84−118.5Murine acetylcholinesterase (MmAChE) (Alzheimer’s target)
−74.8Median docking energy
Nizwanone4b84−123.2Murine acetylcholinesterase (MmAChE) (Alzheimer’s target)
−63.3Median docking energy
Ocotillyl acetate1gsz−144.6Alicyclobacillus acidocardarius oxidosqualene cyclase (AaOSC) (cholesterol-lowering)
2aba−130.1Enterobacter cloacae pentaerythritol tetranitrate reductase (EcPETNR) (antibacterial target)
4jbs−127.7Human endoplasmic reticulum aminopeptidase 2 (HsERAP2) (immune response target)
−70.7Median docking energy
Olibanumol E2ilt−109.5Human 11β-hydroxysteroid-dehydrogenase (Hs11β-HSDH) (diabetes target)
−63.5Median docking energy
Olibanumol F1cgl−110.1Human fibroblast collagenase (HsMMP-1) (arthritis target)
3bt9−108.8Staphylococcus aureus multidrug binding protein (SaQacR)
−36.7Median docking energy
Olibanumol G3bt9−117.4Staphylococcus aureus multidrug binding protein (SaQacR)
−53.0Median docking energy
Olibanumol H3bt9−121.6Staphylococcus aureus multidrug binding protein (SaQacR)
−60.9Median docking energy
Olibanumol I3bt9−115.7Staphylococcus aureus multidrug binding protein (SaQacR)
−63.2Median docking energy
Olibanumol J1rpw−135.5Staphylococcus aureus multidrug binding protein (SaQacR)
1cr6−133.3Murine soluble epoxide hydrolase (MmEPHX2) (anti-inflammatory target)
3bti−132.6Staphylococcus aureus multidrug binding protein (SaQacR)
3gyt−132.1Strongyloides stercoralis nuclear receptor DAF-12 (SsDAF12) (antiparasitic target)
−55.5Median docking energy
Olibanumol J’3l3m−132.3Human poly(ADP-ribose) polymerase-1 (HsPARP-1) (anticancer target)
3g49−129.0Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1) (diabetes target)
3w5e−128.8Human phosphodiesterase 4B (HsPDE4B) (anti-inflammatory target)
3bt9−123.4Staphylococcus aureus multidrug binding protein (SaQacR)
−74.7Median docking energy
Olibanumol K4b84−122.9Murine acetylcholinesterase (MmAChE) (Alzheimer’s target)
3i6m−122.1Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
−64.8Median docking energy
Olibanumol L1ry0−116.2Human prostaglandin F synthase (HsPGFS) (hypertension target)
3g49−111.1Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (Cp11βHSD1) (diabetes target)
−27.6Median docking energy
Olibanumol L’4b84−130.1Murine acetylcholinesterase (MmAChE) (Alzheimer’s target)
−70.7Median docking energy
Olibanumol M1h22−128.4Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
−62.7Median docking energy
Olibanumol N4b84−133.0Murine acetylcholinesterase (MmAChE) (Alzheimer’s target)
−70.9Median docking energy
Trametenolic acid B3ua9−131.6Human tankyrase-2 (HsTANK2) = human poly(ADP-ribose) polymerase-5b (HsPARP-5b) (antitumor target)
3g49−127.1Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) (diabetes target)
3hfb−126.6Human tryoptophan hydroxylase type 1 (HsTPH1) (biosynthesis of serotonin)
1eve−126.5Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
−74.2Median docking energy
Urs-12-ene-3α,11α-diol1h22−120.9Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
−61.1Median docking energy
Urs-12-ene-3β,11α-diol4b84−123.7Murine acetylcholinesterase (MmAChE) (Alzheimer’s target)
−59.8Median docking energy
α-Boswellic acid3g49−110.0Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) (diabetes target)
−65.7Median docking energy
α-Elemolic acid3ua9−152.7Human tankyrase-2 (HsTANK2) = human poly(ADP-ribose) polymerase-5b (HsPARP-5b) (antitumor target)
1c3s−136.9Aquifex aeolicus histone deacetylase (AaHDAC) (anticancer target)
3g49−128.9Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) (diabetes target)
−87.8Median docking energy
β-Boswellic acid3i6m−118.1Torpedo californica acetylcholinesterase (TcAChE) (Alzheimer’s target)
+20.7Median docking energy
β-Elemonic acid3ua9−147.3Human tankyrase-2 (HsTANK2) = human poly(ADP-ribose) polymerase-5b (HsPARP-5b) (antitumor target)
3l3m−133.7Human poly(ADP-ribose) polymerase-1 (HsPARP-1) (anticancer target)
3g49−131.9Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) (diabetes target)
−89.0Median docking energy
δ-Boswellic acid3g49−106.7Cavia porcellus 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) (diabetes target)
−60.7Median docking energy
a PDB: Protein Data Bank code. b The stereochemistry at C(24) was not experimentally determined for 3β-acetoxy-20S,24-dihydroxydammar-25-ene or for eupha-2,8,22-triene-20,24-diol; both diastereomers for each of these compounds were examined in this reverse docking study.
Table
Table 7. MolDock docking energies (kJ/mol) of Boswellia triterpenoid ligands with inflammation-relevant protein targets.
Table 7. MolDock docking energies (kJ/mol) of Boswellia triterpenoid ligands with inflammation-relevant protein targets.
LigandMmEPHX2HsEPHX2HsMMP-1SsPLA2HsPLA2Hs5-LOXMm iNOSHsPI3KγHsIRAK4HsERAP2HsGSTO1HsPDE4B
1cr64hai1cgl2b031j1a3v991m8d2a5u5t1s4jbs5v3q3w5e
(20S)-3,7-Dioxotirucalla-8,24-dien-21-oic acid−113.3−114.1−121.8−127.4−106.9−103.1−88.0−87.7−112.7−107.3−106.0−114.0
11-Ethoxy-β-boswellic acid−80.3−96.3−107.9−100.9−87.3−85.8−71.7−82.5−99.7−104.5−66.8−101.5
11-Keto-β-boswellic acid−75.7−91.8−100.7−94.9−85.3−83.3−64.2−77.2−89.7−99.4−70.72.8
12-Ursen-3,11-dione−73.9−88.8−102.0−102.4−71.2−75.8−63.0−74.9−82.0−98.6−71.4−99.9
12-Ursen-3,24-diol−81.9−84.5−105.5−88.7−93.7−77.4−60.4−76.9−89.8−96.4−87.8−101.1
2,3-Dihydroxy-12-ursen-24-oic acid−78.8−83.9−98.9−100.0−91.1−81.7−30.0−78.6−91.7−96.5−74.8−102.4
20,22-Epoxytirucall-24-en-3-one−98.2−102.5−113.1−111.0−95.7−90.2−89.9−82.5−94.7−105.1−80.9−99.3
24-Nor-3,12-ursadien-11-one−84.1−89.6−99.9−103.4−95.6−77.5−71.8−75.1−64.1−91.7−50.1−83.4
24-Nor-3,9(11),12-oleanatriene−83.4−94.7−99.5−99.9−93.3−70.8−61.0−75.2−59.9−95.3−47.3−90.8
24-Nor-3,9(11),12-ursatriene−83.3−89.4−100.6−99.3−85.5−81.4−65.0−75.3−77.0−86.3−62.2−91.2
3-Acetoxy-12,20(29)-lupadien-24-oic acid−77.8−85.2−115.4−87.5−82.7−83.7−68.4−93.6−59.1−105.0−78.9−97.8
3-Acetoxy-20(29)-lupen-24-oic acid (=3-Acetyl lupeolic acid)−84.1−83.5−117.5−86.7−87.1−82.7−71.8−92.9−79.7−104.5−79.0−92.8
3β-Acetoxy-20S,24R-dihydroxydammar-25-ene−109.7−109.3−124.7−118.5−120.3−100.8−96.7−94.4−106.4−119.1−85.8−116.3
3β-Acetoxy-20S,24S-dihydroxydammar-25-ene−106.2−109.2−121.7−115.6−122.0−100.3−81.5−93.9−109.5−126.1−76.5−111.0
3-Acetoxy-5,12-ursadien-24-oic acid−92.6−78.1−121.1−97.5−81.7−81.0−73.3−83.6−70.4−105.0−70.2−47.3
3-Acetyl-11-keto-β-boswellic acid−87.3−75.6−107.6−102.4−74.0−84.9−67.7−79.7−71.9−93.3−71.6−49.2
3-Acetyl-11α-methoxy-β-boswellic_acid−86.7−91.1−109.3−91.0−75.4−87.3−76.1−79.5−90.0−101.9−69.5−52.0
3-Acetyl-9,11-dehydro-β-boswellic_acid−90.4−80.3−120.6−98.5−94.8−82.7−74.4−82.7−61.1−103.7−84.3−50.3
3-Acetyl-α-boswellic acid−79.0−82.4−109.7−112.7−97.2−82.0−70.5−83.0−83.8−99.7−72.7−91.4
3-Acetyl-β-boswellic acid−91.5−83.1−119.8−99.4−96.2−85.1−69.0−79.4−70.8−90.2−80.6−91.8
3-Hydroxy-20(29)-lupen-24-oic acid (=Lupeolic acid)−103.4−105.0−106.6−82.6−76.6−79.2−72.6−81.8−76.0−103.4−69.5−87.3
3-Oxotirucalla-7,9(11),24-trien-21-oic acid−113.1−113.3−123.3−116.9−113.5−100.5−86.3−92.1−103.6−108.8−99.8−113.2
3β-Hydroxytirucalla-8,24-dien-21-oic acid−110.8−112.1−118.6−123.4−106.5−103.3−97.3−80.7−107.8−109.4−94.6−111.9
3α-Acetoxytirucalla-7,24-dien-21-oic acid−115.5−113.3−129.9−109.8−116.2−91.2−95.4−95.3−109.7−106.1−91.4−104.9
3α-Hydroxytirucalla-7,24-dien-21-oic acid−110.8−115.7−115.4−117.2−110.1−105.7−84.1−86.9−102.8−108.6−82.9−109.8
3β-Acetoxydammar-24-ene-16β,20R-diol−102.8−110.3−125.7−111.2−109.3−97.7−97.0−90.7−107.9−125.2−79.8−115.2
3β-Acetoxylup-20(29)-en-11β-ol−94.6−92.9−109.8−105.6−90.8−86.1−87.1−80.9−93.2−108.2−74.5−41.2
4,23-Dihydroburic acid−101.2−101.6−109.8−120.9−92.0−88.3−72.0−84.3−102.9−110.2−85.3−107.7
6,7-Epoxy-9(11)-oleanen-3-ol−53.0−111.6−100.2−106.3−89.8−79.6−64.5−67.7−66.2−94.9−68.6−87.2
6,7-Epoxy-9(11)-oleanen-3-one−66.0−100.9−105.0−107.8−93.3−75.1−68.5−70.3−40.3−100.6−66.1−106.2
9,11-Dehydro-β-boswellic acid−75.8−85.7−109.8−96.8−93.1−79.8−27.4−73.6−89.5−91.2−83.4−62.6
Boscartene L−83.2−110.2−104.4−115.7−77.4−100.1−81.6−82.0−100.0−108.6−62.6−97.7
Boscartene M−73.8−110.8−114.0−107.0−96.7−102.9−86.8−83.4−76.8−110.4−83.5−91.5
Boscartene N−110.2−113.7−116.6−126.2−106.6−92.9−85.8−87.4−109.6−111.8−100.1−118.6
Dammarenediol II−114.1−112.3−126.2−103.7−110.8−95.8−77.3−87.2−110.3−108.4−101.4−120.5
Dammarenediol II acetate−109.5−109.5−113.4−101.8−115.7−105.2−92.1−97.4−115.2−107.2−77.7−104.9
Eupha-2,8,22-triene-20,24R-diol−111.9−106.1−112.9−121.3−98.2−97.9−80.5−85.9−101.0−106.4−92.8−104.5
Eupha-2,8,22-triene-20,24S-diol−117.2−104.4−113.1−115.5−100.1−97.8−82.6−87.3−99.4−103.0−94.1−105.8
Isofouquierol−116.4−103.7−118.4−113.5−114.9−104.0−96.4−93.2−110.4−114.1−96.8−128.3
Isofouquieryl acetate−107.6−119.6−123.5−122.4−115.8−96.8−103.7−86.4−113.4−124.4−85.2−106.6
Lup-20(29)-ene-2α,3β-diol−101.4−98.8−106.0−95.5−83.0−71.4−87.9−75.4−89.8−107.6−73.2−73.6
Neoilexonol−73.0−87.9−101.1−104.8−71.4−74.7−62.8−69.5−52.3−92.8−73.9−98.0
Neoilexonyl acetate−86.0−86.7−108.2−109.9−83.8−79.4−68.2−74.3−87.5−95.5−69.4−31.7
Nizwanone−81.2−89.7−108.6−89.5−95.3−78.5−60.5−70.1−88.3−98.1−90.9−106.3
Ocotillyl acetate−94.4−96.1−121.5−105.5−107.2−96.7−72.8−84.5−108.2−127.7−77.5−97.2
Olibanumol E−81.7−82.4−101.7−98.7−91.8−82.2−60.6−79.4−92.4−97.9−49.2−99.2
Olibanumol F−85.7−108.9−110.1−86.1−79.7−87.6−65.9−86.4−80.4−95.0−77.3−46.1
Olibanumol G−81.5−95.3−99.3−82.4−70.4−80.0−61.0−77.9−80.8−93.2−54.0−72.7
Olibanumol H−101.1−113.9−107.7−102.3−86.8−82.6−78.1−88.4−94.2−103.8−74.1−55.0
Olibanumol I−96.2−97.4−101.5−93.4−70.6−81.9−75.5−78.2−88.8−96.9−71.6−79.2
Olibanumol J−133.3−119.3−114.2−112.5−117.6−106.1−93.8−88.4−108.3−123.8−99.3−112.3
Olibanumol J’−108.2−119.2−112.7−112.3−118.8−107.7−84.4−84.3−109.2−124.4−84.6−128.8
Olibanumol K−88.8−77.8−110.3−90.5−94.9−77.0−64.9−79.8−76.2−89.9−78.8−82.4
Olibanumol L−78.1−80.8−109.6−91.7−98.1−81.3−67.6−73.8−82.4−97.3−64.1−108.1
Olibanumol L’−85.0−74.1−111.4−97.1−83.9−84.7−67.6−77.4−72.7−92.4−70.0−37.9
Olibanumol M−77.5−89.2−100.1−95.5−57.5−83.9−69.2−77.1−96.5−93.1−63.9−100.0
Olibanumol N−85.0−76.5−103.3−84.5−70.8−86.3−73.6−79.7−87.9−96.8−70.4−50.1
Trametenolic acid B−106.3−107.3−106.9−107.3−107.9−99.7−92.6−84.0−107.6−115.0−92.9−111.6
Urs-12-ene-3α,11α-diol−77.8−78.6−104.3−94.2−85.2−84.4−68.3−77.7−92.2−90.9−64.6−100.1
Urs-12-ene-3β,11α-diol−79.4−74.8−101.3−108.0−71.2−76.9−67.3−69.9−70.9−93.8−61.8−114.1
α-Boswellic acid−77.9−87.8−103.7−100.2−95.0−80.7−64.4−79.4−85.7−94.8−62.5−62.0
α-Elemolic acid−106.5−110.5−113.9−124.4−104.1−99.7−107.1−84.0−108.7−111.1−97.3−110.3
β-Boswellic acid−78.0−87.8−108.9−94.2−90.0−82.5−7.8−76.7−91.1−94.4−85.2−95.5
β-Elemonic acid−112.2−113.8−110.5−123.3−109.6−100.4−92.4−86.3−106.6−107.1−108.0−112.6
β-Elemonic acid−110.0−114.6−120.2−120.4−106.3−99.8−98.8−83.5−109.2−109.0−103.6−116.2
δ-Boswellic acid−76.4−90.4−101.3−89.6−82.5−74.7−69.2−80.7−87.2−96.4−64.4−76.4

Share and Cite

MDPI and ACS Style

Byler, K.G.; Setzer, W.N. Protein Targets of Frankincense: A Reverse Docking Analysis of Terpenoids from Boswellia Oleo-Gum Resins. Medicines 2018, 5, 96. https://doi.org/10.3390/medicines5030096

AMA Style

Byler KG, Setzer WN. Protein Targets of Frankincense: A Reverse Docking Analysis of Terpenoids from Boswellia Oleo-Gum Resins. Medicines. 2018; 5(3):96. https://doi.org/10.3390/medicines5030096

Chicago/Turabian Style

Byler, Kendall G., and William N. Setzer. 2018. "Protein Targets of Frankincense: A Reverse Docking Analysis of Terpenoids from Boswellia Oleo-Gum Resins" Medicines 5, no. 3: 96. https://doi.org/10.3390/medicines5030096

APA Style

Byler, K. G., & Setzer, W. N. (2018). Protein Targets of Frankincense: A Reverse Docking Analysis of Terpenoids from Boswellia Oleo-Gum Resins. Medicines, 5(3), 96. https://doi.org/10.3390/medicines5030096

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop